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LITERATURE REVIEW: DRUG DELIVERY SYSTEMS FOR THE 
POSTERIOR SEGMENT OF THE EYE 
 
 
1 INTRODUCTION 
 
The drug products intended for the treatment of the anterior segment of the eye have 
been dominating the ophthalmic market so far. However, the diseases related to the 
impairment of the posterior segment have become more and more prevalent being at the 
moment the major causes of vision loss in developed countries. These conditions 
include for instance age-related macular degeneration (AMD), diabetic macular edema 
(DME), diabetic retinopathy (DR), posterior uveitis, glaucoma induced retinal and 
neural changes and cytomegalovirus (CMV) retinis, AMD and DR being the most 
prevalent in the USA (Edelhauser et al. 2010). AMD is the main cause for irreversible 
blindness for elderly people older than 65 years, while DR is the most prevalent 
blinding disease in adults aged 20 to 65 years.  
 
AMD is a progressive, degenerative disease affecting the macula in central retina. In its 
late stage it may result rapidly to vision loss. AMD is divided to the two forms: dry 
AMD refers to the geographic atrophy of the retinal pigment epithelium (RPE), 
photoreceptors and choriocapillaris, whereas wet AMD is characterized by choroidal 
neovascularization, abnormal new blood vessel forming of the existing vasculature and 
their penetration to the retina (Lim et al. 2012). These blood vessels are more likely to 
leak blood and fluids, resulting in scar formation. Depending on the form and stage of 
AMD, current treatment lines include e.g. oral antioxidants, fatty acids and carotenoids 
as a preventative therapy in early AMD, laser photocoagulation, photodynamic therapy 
(verteporfin) and intravitreal injections of anti-vascular endothelial growth factor 
(VEGF) agents (ranibizumab, bevasizumab) and corticosteroids. Worldwide, 8.7 % of 
the population between 45–85 years of age has AMD of some stage and form, and by 
year 2020 a number of people suffering from AMD is estimated to be 196 million 
(Wong et al. 2013). 
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Drug delivery to the posterior segment, e.g. to the retinal or choroidal tissues is 
challenging. The eye has many protective static and dynamic barriers that restrict the 
topical bioavailability and drug distribution from the blood circulation to the posterior 
eye tissues. Intravitreal injection is currently a widely used method to administer drugs 
such as anti-VEGF agents to the retina. Intravitreally injected especially low molecular 
weight therapeutics usually have a relatively short half-life and a rapid elimination rate 
from the vitreous. A risk of adverse effects and complications is increased because the 
invasive injections must be repeated frequently in chronic conditions. Since the 
conventional drug delivery modes to posterior segment tissues have either suboptimal 
bioavailability or invasive nature carrying high socio-economical burden with poor 
patient compliance, there is a growing need to improve the drug delivery systems to 
meet the demand of the increasing prevalence of posterior segment disorders by aging 
population. The research of various drug carrier systems such as liposomes, nano- or 
microparticles, implants or iontophoretic methods has emerged, and some of them are 
already launched to market and clinically used. The aim is to develop drug delivery 
vehicles providing improved bioavailability, prolonged drug release and effect, less 
invasive modes or prolonged intervals of administration and decreased side effects to 
posterior segment drug therapies. 
 
 
2 BARRIERS OF DRUG DELIVERY TO THE POSTERIOR SEGMENT 
 
Various protective physiological and anatomical barriers in the eye limit the access of 
drugs and other exogenous substances to the posterior eye consisting of vitreous humor, 
retina, choroid and optic nerve (Figure 1).  
 
The outermost part of the eyeball consists of cornea, sclera and conjunctiva. Cornea 
comprises of three layers: epithelium with tight cell junctions, fibrous water-containing 
tissue stroma and endothelium with large intercellular junctions, which together form a 
strong barrier to topically applied drugs, especially to the large and hydrophilic 
molecules (Prausnitz and Noonan 1998). Sclera is a porous, acellular hydrated tissue 
and it has a big surface area. Sclera is permeable for macromolecules as big as 70 kDa 
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and the permeability is not altered by age (Olsen et al. 1995). Scleral permeability is 
inversely proportional to the molecular radius of the drug, but apparently not dependent 
on the octanol/water distribution coefficient, i.e. lipophilicity (Prausnitz and Noonan 
1998). Due to these characteristics, transscleral route has gained interest among 
researchers as a potential method for drug delivery to the inner eye. Conjunctival 
epithelium forms also an absorption barrier, but it is more permeable than the cornea 
allowing paracellular permeation of macromolecules (Hämäläinen et al. 1997). 
Conjunctiva has a moderate blood and lymphatic vasculature, which causes a fraction of 
the drug to be lost to systemic circulation before it can absorb through the sclera to 
deeper tissues (Maurice and Mishima 1984).  
 
 
Figure 1. Barriers of drug delivery to posterior segment. Adapted from Honda et al. 
2013. 
 
Nasolacrimal tear flow and tear turnover remove the topically applied drug solution 
rapidly from the corneal surface (Lee and Robinson 1986). Unwanted systemic 
absorption via conjunctival blood capillaries or by tear flow to the nasal cavity is a 
remarkable factor that reduces bioavailability of topically administered drugs. Major 
fraction, often more than 50 % but even as high as 90 % of the topically applied dose 
can be systemically absorbed mainly via the conjunctival or nasal mucosal blood flow 
(Järvinen et al. 1995, Lee and Robinson 1986). 
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Anterior blood-aqueous barrier (BAB) consisting of the uveal capillary endothelia and 
ciliary epithelia restricts the drug absorption from the blood to the aqueous humor. The 
natural bulk fluid flow gradient goes from the vitreous to the aqueous. Aqueous humor 
flows through the base of the iris to the suprachoroidal space forming a dynamic 
hindrance to drug entrance to the vitreous humor (Maurice and Mishima 1984). 
 
The vitreous humor is mainly composed of water (98–99 % w/w) and fiber-like solid 
components (type II collagen, hyaluronan, glycosaminoglycans) and enzymes, forming 
a stable gel structure (Mains and Wilson 2013). The size, lipophilicity and charge of the 
drug molecule influence the diffusion through the vitreous. Small or negatively charged 
compounds diffuse more freely without interacting with the vitreous components, 
compared to large or cationic compounds. The drugs are eliminated from the vitreous 
mainly by two routes: via the diffusion to the anterior chamber or across the retinal 
surface (Maurice and Mishima 1984). With aging the vitreal gel volume is decreased 
and the vitreous undergoes degenerative liquefaction (Mains and Wilson 2013). The 
liquefaction process does not occur uniformly through the vitreous as there are liquid 
pockets formed in the vitreous cavity. These age-related changes in the water/gel-ratio 
may affect the drug pharmacokinetics in the vitreous. 
 
The main barriers of drug entrance from the vitreous to the retina are the inner limiting 
membrane (ILM) and the blood-retinal barrier (BRB) (Figure 2). ILM is a basement 
membrane in the interface of the neural retina and the vitreous. BRB consists of the 
retinal pigment epithelium (RPE) forming the outer BRB and the retinal blood 
capillaries comprising the inner BRB, which together form a strong barrier to drug entry 
from the blood flow. Cells in RPE as well as in the retinal capillary endothelium are 
united with tight junctions (Maurice and Mishima 1984). Choroid lines the interior of 
the sclera, providing blood supply to the outer retina. Systemically administered drugs 
can reach the fenestrated choroidal vasculature, but the further paracellular transport to 
the inner retinal tissues is restricted by the tight junctions of RPE. The blood flow rate 
per gram of tissue in choroidal and retinal vasculature is high, but the blood volume 
circulating through the back of the eye is small compared to the whole body blood flow 
(Edelhauser et al. 2010). Small and lipophilic compounds are more likely to penetrate 
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through BRB after systemic administration than large and hydrophilic molecules. The 
active transport system in blood-ocular barriers is able to secrete numerous molecules 
out of the eye or enhance the transportation into the eye (Maurice and Mishima 1984). 
 
 
Figure 2. The inner structure of the retina and choroid. Underlining points out the main 
barriers protecting the inner retina from exogenous substances, inner limiting membrane 
(ILM), retinal pigment epithelium (RPE) and retinal blood vessels. Adapted from Olver 
et al. 2014.  
 
 
3 ROUTES OF DRUG DELIVERY TO THE RETINA  
 
Intravitreal, periocular, topical and systemic routes can be used to deliver drugs to the 
posterior segment. In Figure 3 these routes are schematically depicted and the main 
attributes involved in each of the modes are discussed in separate chapters. 
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Figure 3. Schematic presentation of topical, periocular and intravitreal routes to the 
posterior segment of the eye. Pars plana marked in red color. Adapted from Janoria et 
al. (2007) 
 
3.1  Intravitreal 
 
Intravitreal delivery mode involves direct injection of drugs as solution, implant, 
suspension or particles via pars plana (Figure 3) directly into the vitreous cavity close to 
the retina. Intravitreal delivery enables high local drug concentrations in the vitreous to 
be achieved after a single injection, reducing the systemic exposure and side effects. 
The elimination rate from the vitreous is influenced by several factors of a drug 
molecule. The most important variables to predict the half-life of a low molecular 
weight drug in the vitreous are the number of hydrogen bond donors and acceptors and 
log D7.4 (the logarithm of the octanol-water partition coefficient at pH 7.4) (Kidron et al. 
2012). Higher logD7.4 was shown to correlate with shorter half-life and more rapid 
elimination, whereas increased hydrogen bonding is related to prolonged half-live in the 
vitreous. These observations may possibly be due to the increased membrane 
permeability related to high logD7.4 and low polarity. High molecular weight is 
associated to longer half-life, macromolecules such as proteins generally residing longer 
in the vitreous compared to small molecules (Durairaj et al. 2009). 
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If the disease state requires sustained drug therapy, the rapid drug elimination from the 
vitreous results in the need of frequently repeated injections. For example, intravitreally 
administered anti-VEGF agents, e.g. ranibizumab (Lucentis), aflibercept (Eylea) and 
bevacizumab (Avastin, off-label use) are at the moment the standard drug treatment of 
neovascular AMD. In rabbits, the vitreal half-lives have been measured to be 2.9 days 
and 4.3 days for ranibizumab and bevacizumab, respectively (Bakri et al. 2007). In 
clinical trials the mean VEGF suppression time for ranibizumab was 37 days, ranging 
inter-individually from 26 to 69 days during three-year period (Muether et al. 2013). 
These anti-VEGF therapeutics are initially given once a month. However, flexible 
dosing regimen starting with monthly injections of ranibizumab for three months and 
then as needed based on re-treatment criteria (in this study, average 5.6 injections given 
in 12 months period) has resulted in comparable outcomes in terms of safety and 
efficacy when compared to monthly given injections in the treatment of neovascular 
AMD (Holz et al. 2011). Based on the current treatment lines in the EU, three monthly 
injections of ranibizumab may be needed when starting the treatment of wet AMD or 
macular edema, and thereafter the injection interval is determined by the treating doctor 
based on the disease activity (EMA, Lucentis EPAR summary for the public, 2014).  
 
In addition to inconvenience caused to patients, frequently given injections increase the 
cumulative risk to complications and side effects including retinal detachment, 
increased intraocular pressure, intraocular hemorrhage, endophthalmitis, and cataract 
development (Jager et al. 2004). Moreover, the costs of this procedure are high due that 
the injections must be administered by a specialized physician.  
 
Intravitreal route has been used to deliver several types of drugs from low molecular 
weight drugs to large macromolecules including antibiotics, anti-inflammatory 
compounds, anticancer and anti-VEGF agents (Peyman et al. 2009). Despite the risk of 
complications involved, intravitreal injection bypasses the anatomical barriers of the 
eye, making it at the moment the most efficient route to deliver drugs to the posterior 
eye tissues. Improved approaches of intravitreal delivery are based on technologies 
prolonging the release of the drug and localization to the target tissue, so that the 
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frequency of the injections given would be reduced (Thakur et al. 2014). The need to 
study the possibilities of less invasive methods is still at high importance. 
 
3.2 Periocular 
 
Periocular delivery refers to the administration of therapeutics to the regions 
surrounding the eye as a form of injection of drug solution, implant or other mechanism. 
Periocular modes include e.g. subconjunctival, sub-Tenon, peribulbar, retrobulbar and 
posterior juxtascleral. First two of these have been assumed to be the most promising 
routes for drug delivery to the retinal tissues. The drug is absorbed mainly via 
transscleral pathway (Raghava et al. 2004).  
 
In subconjunctival delivery the formulation is placed underneath the conjunctiva 
covering the sclera. Sub-Tenon injection is a widely used technique in administration of 
local anesthetics during ocular surgery, involving the drug delivery via blunt-tipped 
cannula to the Tenon’s capsule, an avascular fascial layer around the globe of the eye 
(Canavan et al. 2003). Retrobulbar injection is made with a blunt needle within the 
conical compartment formed by four extraocular muscles behind the eyeball (Raghava 
et al. 2004). Peribulbar injection differs from retrobulbar that the muscle cone is not 
entered, but the injection is given externally to it. Peribulbar route is considered safer 
compared to retrobulbar, but less effective in anesthetizing the globe. Posterior 
juxtascleral method is based on drug delivery with blunt, curved cannula to the outer 
surface of the sclera. A relatively new route for drug delivery is suprachoroidal space 
located within sclera, externally to choroid. Applications using e.g. microneedles in 
delivering therapeutics to the posterior segment via suprachoroidal route are further 
discussed in chapter 4.4.2. 
 
The drug entrance from periocular spaces into the posterior chamber can happen via 1) 
anterior chamber, 2) systemic circulation or 3) direct penetration pathway, the latter of 
which being the most relevant in delivering drugs to the posterior chamber (Ranta and 
Urtti 2006). Anterior route involves drug diffusion across the sclera and ciliary body to 
anterior chamber, and further to posterior chamber. Systemic circulation route refers to 
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the absorption of drug from periocular spaces via conjunctival or choroidal blood 
vessels to the systemic blood flow, and later back to the eye by the blood flow. In direct 
pathway the drug enters directly from the periocular space through the sclera, and then 
the barriers depend on the position where the dosage form has been placed. If the 
formulation is placed anteriorly, drug may have to pass the layers of ciliary body in 
order to reach the posterior chamber. Posterior placement requires drug to be penetrated 
through choroid, RPE and neural retina. 
 
The bioavailability of periocularly administered drugs is decreased due to the rapid 
blood flow of the conjunctiva and choroid. The particle size is a key factor affecting the 
clearance from the site of administration. Amrite and Kompella (2005) compared the 
disposition of 20 nm, 200 nm and 2 µm sized polystyrene particles after subconjunctival 
injection. Particles bigger than 200 nm were observed to retain substantially longer in 
subconjunctival space after the injection, over 50 % of the injected dose remained at the 
site of administration after 60 days post-injection. 20 nm sized particles however were 
cleared to 8 % of the dose administered in a week, and were not detectable anymore 
after 60 days. Based on these observations, the particulate systems over 200 nm of 
diameter would therefore be preferential over smaller particles when considering 
periocular administration. 
  
Besides nano- and microparticles, macromolecules have also been shown to retain in 
the periocular spaces and reach the posterior tissues. 70 kDa dextran molecules have 
been delivered to the retina through transscleral diffusion followed by a subconjunctival 
injection (Kim et al. 2002). Ambati et al. (2000) used an implantable osmotic pump in 
rabbits to deliver FITC-labelled antibodies transsclerally to the choroid and retina 
without significant enzymatic degradation or systemic absorption. Increased levels of 
fluorescence in retinal and choroidal tissue samples compared to baseline were observed 
for 28 days. The fluorescence levels in the vitreous humor, aqueous humor and orbit 
were negligible, and there was practically no fluorescence in plasma or non-implanted 
eye indicating non-significant systemic absorption. Protein precipitation studies of the 
homogenized tissue samples showed that the antibody molecules stayed intact and were 
not cleaved from the FITC during the study. The sclera acts like a sponge due to its high 
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hydration degree, surface area and hypocellularity, being therefore a promising pathway 
to macromolecule delivery. 
 
Other barriers and factors affecting the bioavailability of the periocularly administered 
drugs are tight cell junctions of RPE, efflux membrane transporters and binding of 
drugs to the tissue proteins (Raghava et al. 2004). Especially lipophilic drugs can bind 
to ocular melanin, a pigment found in e.g. uvea and RPE, which can alter the drug 
pharmacokinetics and therapeutic response due to the drug retaining in these pigmented 
tissues (Pitkänen et al. 2007). 
 
Periocular route is considered as one of the safest drug delivery modes for posterior eye 
(Edelhauser et al. 2010, Raghava et al. 2004). There is safety information available 
about periocular injections mainly concerning ocular anesthesia. Among periocular 
administration modes the retrobulbar injection has the highest risk of severe 
complications, including retrobulbar hemorrhage and perforation of the globe. Most 
common adverse effects related to sub-Tenon injection are swelling and hemorrhage of 
the conjunctiva, but the method is considered rather safe because of the use of blunt 
cannula instead of sharp needles (Canavan et al. 2003). 
 
Especially sustained release enabling technologies such as gels, nano- or microparticle 
based or implantable depot systems have been able to deliver drugs to the retina and 
would be preferable for periocular delivery (Raghava et al 2004). Although periocular 
routes have inferior bioavailability compared to the intravitreal injection, they possess 
several advantages. Bioavailability in posterior segment after periocular administration 
appears to be greater when compared to the systemic or topical route (Ranta et al. 
2010). Periocular delivery is less invasive than intravitreal since the globe of the eye is 
not punched. It is better tolerated by patients and intravitreal injection associated severe 
complications such as retinal detachment can be avoided. Periocular route remains an 
appealing option for intravitreal route especially for the treatment of mild or moderate 
posterior segment diseases or in preventative therapy (Edelhauser et al. 2010). 
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3.3 Topical 
 
Topical administration from eye drops is the most common way to deliver drugs to the 
anterior part (cornea, conjunctiva, sclera, iris, ciliary body, aqueous humor, lens) of the 
eye. Around 90 % of the ophthalmic drug products are for topical use (Rowe-
Rendleman et al. 2014). Besides eye drops, topically administered dosage forms on 
market include for instance ointments and suspensions. Topical administration is an 
easy, non-invasive and patient friendly method, but in most cases inefficient in 
delivering therapeutic concentrations of drugs to the retina (Edelhauser et al. 2010). On 
their way to the retina, topically administered drugs encounter more local clearance 
mechanisms than the drugs administered by any other route, besides that the diffusion 
distance from surface of the eye to posterior tissues is much more longer. Generally, 
maximum 5 % of the topically administered drug dose from conventional eye drop 
formulation is absorbed into the eye, and fraction that reaches the vitreous is calculated 
to be even smaller and often below therapeutic concentration: intravitreal bioavailability 
percentages of as low as 0.0001–0.0004 % have been reported (Maurice 2002).  
 
Generally, topically administered drugs can enter to posterior segment via two main 
routes: corneal or conjunctival (non-corneal) route. Corneal route involves drug entry 
via cornea, iris, lens and ciliary body, and drug diffusion through the vitreous. In non-
corneal route the drug absorption occurs through the conjunctiva, sclera, choroid and 
RPE. Lipophilic drugs are more likely to permeate through the cornea than hydrophilic 
molecules. Conjunctival route is assumed to be in higher importance regarding to drug 
delivery to posterior segment, especially for large and hydrophilic molecules having 
poor corneal permeability such as inulin, timolol, gentamicin and bimatoprost (Maurice 
2002, Hughes et al. 2005).  
 
Aims to increase bioavailability after topical administration are based on enhancing the 
penetration through the rate limiting barriers cornea, conjunctiva and sclera, and 
prolonging the drug residence time on the surface of the eye with sustained-release 
formulations. Edelhauser et al. (2010) listed few approaches how the penetration 
through restricting membranes can be improved. These methods include e.g. using 
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preservatives in topical formulations to open tight cell junctions, increasing drug 
lipophilicity by using pro-drugs or surfactant-based permeation enhancers, or binding 
the drugs to carriers that are substrates to influx membrane transporters. Sustained-
release formulations such as gels, suspensions, ointments, biomucoadhesives, contact 
lenses, and conjunctival cul-de-sac implant devices have previously been studied for 
topical delivery.  
 
In humans the precorneal half-life of a drug in simple solution is within 1–3 minutes 
before being washed away by the tear flow (Loftsson et al. 2008). Viscosity increasing 
agents like hydroxyl methylcellulose, polyvinyl alcohol (PVA), or natural polymers like 
hyaluronic acid have been used in the eye drop formulations to prolong the contact time 
in the surface of the eye (Ali and Lehmussaari 2006). For instance topical gellan gum 
based in situ gelling formulation delivered significantly more aesculin to rabbits 
posterior eye tissues than aesculin solution (Chen et al. 2012). The area under the curve 
(AUC0-t) and maximum concentration (Cmax) of aesculin in the retina and choroid were 
three times and two times higher in the gel formulation treated group than in the 
solution group, respectively. 
 
Solubility of the drugs in tear fluid can be modified for example complexing them with 
cyclodextrins, oligosaccharides forming a hydrophilic outer surface and a lipophilic 
core (Loftsson et al. 2008). Since no covalent bonds are formed, there is an equilibrium 
between cyclodextrin bound drug and free drug. Complexation with cyclodextrins 
increases the water-solubility of lipophilic drugs in the tear fluid resulting to the higher 
fraction of a drug to be available for permeation in the corneal surface. Several other 
carrier systems such as liposomes, micelles and polymer based nanoparticle systems 
have been studied to improve the ocular absorption through biologic barriers of the eye. 
For instance, Mitra et al. (2010) have patented a nanomicellar formulation that was 
shown to deliver therapeutic concentrations of several poorly water-soluble drug 
compounds, such as corticosteroids, calcineurin inhibitors and mTOR inhibitors to the 
back of the eye. Topical delivery to posterior segment of was established with targeted 
small liposomes by Lajunen et al. (2014). Transferrin-conjugated 80 nm sized or 
smaller liposomes were shown to reach RPE after topical administration in rats. The 
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size and targeting were critical factors enabling the retinal delivery, since non-targeted 
liposomes and bigger liposomes over 100 nm were not detectable in RPE. 
 
The research about the importance of active membrane transporters in ocular 
pharmacokinetics has emerged during the past years, since many of the ophthalmic 
drugs have been found out to interact with the transporters found in corneal, 
conjunctival and RPE membranes (Mannermaa et al. 2006). Transporters that have been 
found to express in corneal epithelium are for instance oligopeptide transporter PepT1, 
amino acid transporters LAT1 and ASCT1, monocarboxylate transporters and p-
glycoprotein and multi-drug resistance proteins (MRP). RPE regulates the transport of 
nutrients and waste molecules, as well as ion and fluid balance in highly metabolically 
active retina, expressing several influx and efflux transporters, for instance taurine 
transporter (TAUT), several monocarboxylate and organic cation transporters, MRP and 
p-glycoprotein efflux pumps. For example, brimodine is reported to achieve 
concentration levels above therapeutic levels in posterior eye tissues when administered 
as eye drops (Acheampong et al. 2002). It is supposed that active transportation of 
brimonidine via organic cation transporters in the conjunctiva, RPE and retina has a role 
to the drug levels achieved (Mannermaa et al. 2006). 
 
The consensus about how the exact properties like charge, molecular weight, and 
lipophilicity affect the topical permeation to posterior tissues is not yet fully clear 
(Boddu et al. 2014). Despite all the obstacles, there are some cases in which significant 
drug concentrations in posterior eye have been achieved after topical administration. 
The increasing research and knowledge of the membrane transporters in rate limiting 
barriers can bring new prospects to the topical drug delivery. Topical route is an 
attractive option to ocular drug delivery because of its convenience, good patient 
compliance and minimal invasiveness. If the problems in bioavailability in posterior 
tissues can be improved, topical dosage forms would enable self-administration with 
lower costs reducing the overall burden in treatment of chronic eye diseases. 
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3.4 Systemic  
 
Systemic route includes the absorption to the eye from systemic blood flow after e.g. 
intravenous or oral administration of therapeutics. Because of blood-ocular barriers 
BRB and BAB the drug absorption from systemic blood flow to the anterior and 
posterior segments of the eye is limited especially concerning large and hydrophilic 
molecules (Hughes et al. 2005). Drug lipophilicity correlates with the rate of penetration 
through the blood-ocular barriers. The principal route to the anterior and posterior 
chambers from blood stream is via BAB, i.e. iris and ciliary body (Maurice and 
Mishima 1984). The iris and bulk fluid flow from the posterior chamber through the 
pupil into the anterior chamber form a hindrance to molecules that penetrate through the 
BAB to the aqueous humor (Hughes et al. 2005). In posterior segment, the fenestrated 
endothelium of choroidal blood vessels allow the systemically administered drugs to 
reach the choroid relatively easily. Most of the drug compounds used in posterior eye 
diseases cannot cross the BRB to be efficiently absorbed further to the inner retinal 
tissues. Highly lipophilic compounds such as chloramphenicol and benzyl penicillin can 
cross the BRB compared to the polar or charged compounds. Only a small fraction of 
the whole blood volume circulates through the posterior eye. Drug concentration 
dilution to the systemic blood volume requires high doses to be administered, which 
increases the risk of systemic side effects especially concerning drugs with narrow 
therapeutic indexes (Eljarrat-Binstock et al. 2010). 
 
Posterior eye drug delivery via systemic route may significantly be improved by active 
or passive targeting to pathological tissue. The uptake of transferrin and/or arginine-
glycine-aspartic acid (RGD) -peptide conjugated anti-VEGF intraceptor plasmid loaded 
poly lactic-co-glycolic acid (PLGA) nanoparticles by retinal cells was studied in rats 
after intravenous administration (Singh et al. 2009). These peptides were aimed to target 
the laser-induced choroidal neovascularization. RGD is known to bind to integrin 
receptors overexpressed in angiogenesis and transferrin is also actively taken up by 
retinal cells possibly due to the overexpression of transferrin receptors related to AMD. 
The ligand-conjugated targeted nanoparticles were observed to accumulate to the laser-
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treated eyes after 24 hours of systemic administration, but not to the non-laser treated 
control eyes.  
 
The utilization of the active transporters may have a significant role in systemic drug 
delivery of molecules that are substrates to influx or efflux membrane transporters 
(Mannermaa et al. 2006, Hosoya and Tachikawa 2009). Transporters in outer BRB or 
RPE have been shortly reviewed in chapter 3.3. Inner BRB supplies the photoreceptors 
and other neuronal cells of the retina with energy from the blood stream. The influx 
transporters in inner BRB carry hydrophilic nutrients e.g. glucose, amino acids, 
vitamins and nucleosides to the neural retina. The transporters of BRB may have an 
important role in drug transportation to the back of the eye, by targeting blood to retina 
influx transporters (e.g. glucose transporter 1, monocarboxylate transporter 1, LAT1 
and TAUT) or avoidance or inhibition of the retina to blood efflux transporters (e.g. p-
glycoprotein, MRP and several types of organic anion transporters) the drug transport 
from blood to the retina may be enhanced. 
 
Several compounds, such as protein kinase C inhibitors, anti-VEGF agents, carbonic 
anhydrase inhibitors, retinoids and antimicrobial compounds have been successfully 
delivered to the eye via systemic route (Hughes et al. 2005). Only drugs that are either 
lipophilic enough or substrates of active transporters are expected to cross the BRB to 
achieve sufficient drug concentrations in the posterior eye.  Although the systemic route 
is less invasive to the eye, a critical disadvantage and safety risk is related to the 
systemic side effects since high doses of drugs has to be administered in order to 
achieve therapeutic concentrations in the posterior eye target tissues. To conclude, 
regarding the efficacy and safety systemic route appears to be non-optimal at the 
moment in posterior segment therapy. The utilization of the targeting ligands to RPE, 
choroid or retinal capillaries or active transportation through BRB may open prospects 
to the systemic delivery mode. 
 
The possible routes for drug delivery to the posterior segment, barriers involved and 
related advantages and disadvantages are summarized in Table 1. Based on the current 
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knowledge, the most efficient though most invasive route of these is the intravitreal 
mode.  
 
Table 1. Barriers, advantages and disadvantages related to the routes for drug delivery 
to the posterior segment. Modified from Kaur and Kakkar (2014) and Edelhauser et al. 
(2010). 
Mode  Pathway Barriers involved Advantages Disadvantages 
   
   
   
  I
nt
ra
vi
tr
ea
l  
Direct delivery to 
the vitreous 
chamber via pars 
plana 
Vitreous humor,  
ILM, neural retina, 
BRB, outward 
vitreoretinal 
clearance, clearance 
via anterior chamber 
 
- Local and direct 
delivery 
- High therapeutic 
concentration 
achieved 
- Highest vitreal 
bioavailability  
- Invasive 
- Highest risk of 
complications such as 
retinal detachment related 
to injection  
- Rapid clearance from the 
vitreous à repeated 
injections required  
   
   
   
Pe
ri
oc
ul
ar
  
Drug is delivered 
mostly via 
transscleral 
pathway 
Sclera, BRB, choroid, 
conjunctiva, 
membrane 
transporters 
- Less invasive to 
the globe 
- Sufficient 
therapeutic drug 
concentration 
potentially 
achieved in the 
retina 
- Rapid clearance due 
blood flow 
- Systemic side effects 
-Inferior efficiency than in 
intravitreal mode 
- Side effects e.g. tissue 
hemorrhage 
T
op
ic
al
 
Absorption 
through cornea, 
conjunctiva and 
sclera 
Cornea, BRB, 
membrane 
transporters, diffusion 
through the aqueous 
and vitreous 
chamber, clearance 
via aqueous humor 
flow  
- Good patient 
compliance 
- Least invasive 
- Usually low 
bioavailability in posterior 
segment 
- Can cause systemic side 
effects due to unwanted 
systemic absorption 
- Temporal blurring of 
vision 
   
  S
ys
te
m
ic
 
Absorption from 
blood flow 
through choroid 
and via blood 
ocular barriers 
BRB, BAB, 
membrane 
transporters, 
clearance via aqueous 
humor flow 
- Minimal local 
drug exposure and 
risk of ocular 
adverse effects 
 
- Systemic side effects due 
to the need of high 
administration doses 
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4 DRUG DELIVERY SYSTEMS 
 
The purposes of drug delivery system design are divided to three main goals: 1) 
enhancing the absorption and permeation through the limiting barriers to the target 
disease area, 2) to enable time-controlled release, and 3) to target the drug molecules 
spatially by using active or passive methods (Yasukawa et al. 2004). This chapter 
focuses on reviewing some of the vast amount of the studied drug delivery systems that 
aim to answer these challenges and enhance the delivery of therapeutic substances to the 
posterior segment of the eye. The properties of the different categories of dosage forms 
are collected in Table 2 (page 28). 
 
4.1 Implants 
 
Implants are among the most widely studied drug delivery vehicles for posterior 
segment diseases, and several products have gained marketing authorization. Implants 
are made usually of biocompatible non-degradable or biodegradable polymeric 
materials that can supply the sustained release of a drug for a long period of time, for 
months to even years (Bourges et al. 2006). Implants are therefore best suited for 
chronic conditions requiring long-term drug therapy. The devices can be formulated to 
release the drug from inside a reservoir through a semi-permeable membrane, or drug 
can be mixed into a polymer matrix. Possible insertion sites of the implant include 
topical, intravitreal, sub-Tenon, intrascleral, subconjuctival and suprachoroidal places 
(Yasin et al. 2014). Non-biodegradable implants have remained to be more preferred 
over biodegradable ones because of the more desirable and controllable drug-release 
profile. In addition, they can be more easily removed if adverse effects occur. Thermo-, 
pH- or light-sensitive polymers can also be combined with conventional polymers in 
order to obtain stimuli-responsive targeted drug delivery approach to implantable 
devices. 
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4.1.1 Non-biodegradable implants 
 
These implant types compose of drug encapsulated into an implant coated with 
diffusion rate limiting non-biodegradable membrane. Polyvinyl alcohol (PVA), ethylene 
vinyl acetate (EVA) and silicon are the most used polymers for non-biodegradable 
implants (Yasin et al. 2014). PVA is often used as a release rate controlling framework 
of the implant. (Bourges et al. 2006). EVA and silicon are hydrophobic materials, 
having good permeability to lipophilic drugs but being rather impermeable to 
hydrophilic compounds. Almost zero-order kinetics and very long lasting constant rate 
release can be achieved with reservoir type non-biodegradable implant devices. The 
disadvantages of these implants are that they must usually be surgically inserted and 
removed after the emptying, with increased risks related to the additional surgical 
operation. For example retinal detachment, severe vitreous hemorrhage and 
endophthalmitis have been reported as complications related to ganciclovir implant 
(Vitrasert) procedures (Lim et al. 1999). 
 
Vitrasert was the first ocular implant to be approved by FDA in 1996, containing 
ganciclovir for the treatment of CMV retinitis in patients with AIDS. Implant is placed 
intrasclerally to pars plana. A drug tablet is coated with non-degradable polymer 
membranes, PVA on the inner membrane and EVA on the outer membrane (Musch et 
al. 1997). The clinical effect has been studied to last for up to 8 months (Muccioli and 
Belfort 2000). There is evidence though suggesting that in the era of highly active 
antiretroviral therapy, the systemic therapy seems to be more effective in dissemination 
of CMV and survival improvement than the intravitreal ganciclovir implant (Jabs et al. 
2013). Vitrasert was voluntarily withdrawn from EMA by the market authorization 
holder in 2002 and is also discontinued by FDA at the moment. 
 
Retisert is another intravitreal implant inserted surgically to pars plana, containing 
fluocinolone acetonide. The drug consisting core is coated with silicon having a small 
release orifice (Jaffe et al. 2006). PVA membrane is placed between the core matrix and 
a release orifice to form a diffusion barrier. This implant can supply constant drug 
release for 3 years. Retisert implant was approved by FDA in 2005 and it is used for the 
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treatment of chronic non-infectious uveitis. However, the application was withdrawn 
from EMA in 2007. Among the reasons of withdrawal was that the implant did not 
suppress reoccurring of the disease longer compared to the standard care, also some side 
effects such as increased intraocular pressure, cataracts and eye pain were observed 
(EMA, Questions and answers on the withdrawal of the marketing application for 
Retisert, 2007).  
 
Another fluocinolone acetonide implant using the similar technology, Iluvien, is 
indicated to treatment of DME. The drug is loaded in PVA matrix inside a polyimide 
tube, releasing the drug at a constant rate for 3 years (Campochiaro et al. 2010 and 
2012). Due to its small size (3.5x0.37 mm) Iluvien can be injected to vitreous cavity 
through a 25-gauge needle. As being non-biodegradable, the possible accumulation of 
the implants into the vitreous may cause problems (Yasin et al. 2014). There are still 
limited data published about the implant removal, but at least in one case report the 
implant that had been migrated to the anterior chamber was successfully removed and 
inserted back to the vitreous cavity for two patients (El-Ghrably et al. 2015). Iluvien has 
received marketing authorization by FDA in 2014, and is also accepted to clinical use in 
17 EU countries after a decentralized procedure. 
 
I-vation is another non-biodegradable intravitreal implant coated with titanium, PVA 
and EVA, aiming to supply the release of triamcinolone for 2 years (Wang et al. 2013). 
Helical shaped implant is inserted through a pars plana sclerotomy. The phase IIb 
studies for treatment of DME have been terminated (NCT00692614). 
 
Interesting approach to implantable technology is refillable port-delivery system 
implant that has been under development to enable sustained release of commercially 
available anti-VEGF agents (De Juan et al. 2014). It was compared to monthly 
intravitreal injections of ranibizumab for 12 months in phase I clinical trials for AMD, 
and resulted in improvements in best corrected visual acuity (BCVA), reduction in 
macular thickness and choroidal neovascularization leakage (Biro 2013). With refillable 
or flushable feature the implant can easily be emptied in case of an adverse effect or if 
the patient can benefit a pause in drug therapy (De Juan et al. 2014). 
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4.1.2 Biodegradable implants 
 
Commonly used biodegradable polymers include for example synthetic polylactic acid 
(PLA), polyglycolic acid (PGA), PLGA, polycaprolactones, polyanhydrides and 
polyorthoesters (Bourges et al. 2006). The advantage over non-biodegradable implants 
is that biodegradable implants erode by enzymatic and non-enzymatic hydrolysis 
reactions, and therefore usually need no surgical removal. However, the drug release 
from the biodegradable implants is not as steady as from non-degradable implants. The 
drug release profile usually follows a three-phase pattern including an initial burst 
release followed by a diffusive phase, and a final burst release caused by bulk erosion. 
This can be an undesirable feature since the release kinetics as constant as possible are 
usually preferred in long-term therapy. 
 
PLGA is the most extensively studied biodegradable polymer (Yasin et al. 2014). 
Dexamethasone loaded PLGA matrix based implant Ozurdex (formerly Posurdex) is 
clinically used for the treatment of macular edema and non-infectious uveitis. Due to its 
smaller size it can be injected intravitreally through a 22-gauge needle. The clinical 
response with 0.7 mg dose of dexamethasone lasts for 6 months (Herrero-Vanrell et al. 
2011). In pharmacokinetic studies conducted on monkeys it was confirmed that the drug 
release profile from the device is biphasic: when reaching the plateau after a couple of 
days of the insertion the dexamethasone concentrations in the retina and vitreous were 
high for two months (Chang-Lin et al. 2011). Thereafter, the remaining fragments of the 
implant continued releasing the drug and lower concentrations of dexamethasone were 
detected for four months. No significant final burst was observed. Since the implant is 
not fixed in the posterior chamber it can be moved away from the injection site. 
Complications after the implant migration from the vitreous to the anterior chamber 
have been reported (Pardo-López et al. 2011). 
 
Verisome platform involves injection of an in-situ forming coalescent material into the 
vitreous, and the release of the drug by slow degradation up to one year (Wang et al. 
2013). It can be loaded with several types of drugs from low molecular weight 
compounds to macromolecules. Besides the lead product IBI-10090 proceeded to phase 
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III clinical trials for the inflammation related to the cataract surgery (NCT02006888), 
Icon biosciences has several Verisome technology based products in the pipeline for the 
posterior segment diseases DME, wet and dry AMD and uveitis (Pipeline, Icon 
biosciences 2015) 
 
4.1.3 Cell encapsulation 
 
Encapsulated cell technology (ECT) implies the immortalized cell lines genetically 
modified to produce therapeutic proteins. The cells are capsulated into a semi-
permeable implant, which allows the exchange of nutrients and cell metabolic products, 
as well as the diffusion of the secreted proteins from the implant. Renexus, also known 
as NT-501, from Neurotech Pharmaceuticals contains ARPE-19 cells secreting human 
ciliary neurotrophic factor (CNTF) for at least one year and up to 18 months from a 
non-biodegradable device. In clinical trials it has been well tolerated and effective in 
slowing the progression of vision loss in dry AMD (Jaffe 2010). NT-501 has received 
an orphan drug designation from FDA for the treatment of macular telangiectasia and 
retinitis pigmentosa. Neurotech has also several other same technique based ECT 
products in the pipeline modified to secrete for instance anti-VEGF antibodies (ECT 
pipeline 2015, Neurotech pharmaceuticals).  
 
4.2 Nano- and microparticles 
 
This chapter focuses mainly on the drug carrier particles consisting of polymeric or 
protein-structured macromolecules. Particles under size 1 µm are referred as 
nanoparticles and particles over 1 µm are termed microparticles. They can be prepared 
in forms of spheres or capsules, in which the drugs can be dissolved, encapsulated or 
entrapped into, or attached, adsorbed or absorbed (Janoria et al. 2007). Spherical type 
particles consist of a polymer matrix in which the active ingredient is dispersed, 
whereas capsule particles resemble a reservoir having the drug inside a core, surrounded 
by a polymer layer. Compared to the implant devices often prepared from the same 
polymer materials, the advantages of nano- and microsized particles are that they can be 
injected through a needle, which is an easier operation compared to the surgical 
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insertion of an implant. Nanoparticles can also be taken up by cells by different 
internalization pathways, depending on their physicochemical characteristics such as 
size, shape, charge, surface coating and attached ligands as well as the target cell type 
(Kompella et al. 2013) 
 
The biomaterials used to prepare nano- or microparticles can be derived from natural 
sources like albumin, chitosan, hyaluronic acid or gelatin, or they can be synthesized 
such as PLGA, PLA, PVA, poly (ethylene-co-vinyl acetate), polyimide, 
polymethylmethacrylate, polyalkylcyanoacrylate and polycaprolactone (Diebold and 
Calonge 2010). The most commonly used polymers are PLGA and PLA, which are 
approved by FDA and are biodegradable in vivo. 
 
Nanoparticles can prolong the release of encapsulated compound acting as a depot, and   
can be internalized by cells. Intravitreally injected PLGA nanoparticles average 230 nm 
of diameter were able to release dexamethasone in controlled rate at least for 50 days in 
rabbit eyes (Zhang et al. 2009).  Bourges et al. (2003) studied the kinetics of average 
140 nm sized intravitreally injected fluorochrome-labelled PLA nanoparticles in rat 
eyes. They observed a rapid diffusion of the nanoparticles through the vitreous and 
accumulation within the RPE cells 18–24 hours post-injection, encapsulated fluorescent 
dye staining the retina uniformly. PLA nanoparticles sustained in the RPE cells for four 
months, whereas the free fluorochrome faded gradually and was hardly detectable after 
one week after the intravitreal injection. 
 
Another promising biomaterial albumin is the main protein in human blood, and besides 
its biocompatibility it possesses several attributes making it a good candidate for drug 
and gene delivery material. Albumin increases the drug solubility and half-life, 
decreases toxicity and protects the molecules from oxidation (Kompella et al. 2013). 
Kim et al. (2009) studied the vitreal movement of the human serum albumin 
nanoparticles with either anionic or cationic surface charges. Negatively charged 
albumin particles were more easily diffused through the vitreous and accumulated to the 
RPE than positively charged particles. Cationic particles were more likely to bind to the 
vitreous due to the electrostatic interaction between the negatively charged vitreal 
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glycosaminoglycans. Ganciclovir was delivered in sustained manner from bovine serum 
albumin nanoparticles in rats and the nanoparticles remained in the vitreous, retina, 
BAB, and ciliary body at least for two weeks after intravitreal injection (Merodio et al. 
2002). No inflammatory reactions or other harmful effects to ocular tissues were 
observed. 
 
Dendrimers are branched, tree-like, usually water soluble polymers able to present 
different neutral, negative or positive functional groups on their surface increasing their 
ability to targeting and facilitating easier preparation (Yavuz et al. 2015). 
Polyamidoamine (PAMAM) dendrimer formulations are the most studied dendrimers 
for drug delivery purposes. PAMAM dendrimers with either anionic or cationic surface 
charge were loaded with dexamethasone and pharmacokinetics studied in rats following 
topical and subconjunctival administration. The dendrimers enhanced both the topical 
and transscleral permeation and ocular drug distribution, and increased concentrations 
of dexamethasone were measured in retina especially with anionic PAMAM dendrimer 
formulations. 
 
Other particle type carriers that have been studied in posterior segment drug delivery 
include e.g. solid lipid nanoparticles, micelles and liposomes. Micelles are composed of 
ampiphilic polymers or surfactants, typically polyethylene glycol (PEG), forming a 
similar like colloidal structures than liposomes but are composed of monolayers instead 
of bilayers. Liposomes are reviewed more thoroughly in chapter 4.3. Few reports about 
the use of metallic and other inorganic nanoparticles exist, and their utilization is 
expected to gain interest in the future (Diebold and Calonge 2010). Since nano- and 
microparticles can be modified also to reach the intracellular targets, they have potential 
to deliver gene-derived therapeutics to the posterior eye. The nanosized particles can 
cause vitreal clouding, whereas bigger microsized particles tend to aggregate to the 
bottom of the eye (Yasukawa et al. 2004). Main challenges related to the micro- and 
nanoparticle based systems include formulation stability, controllability of particle size 
and drug release rate, and sterile manufacturing scale-up (Eljarrat-Binstock et al. 2010). 
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4.3 Liposomes  
 
Liposomes are composed of natural or synthetic lipids arranged to form sphere-shaped 
vesicles enclosing water to their core with one or several lipid bilayers. Water-soluble 
drugs can be encapsulated into the aqueous space of the liposome core, and lipophilic 
compounds into the lipid bilayer. Different types of liposomes include unilamellar, 
multilamellar or multivesicular ones. Liposomes can also be classified based on their 
size to small unilamellar vesicles at a range of around 20–200 nm, large unilamellar 
vesicles ranging from 200 nm to 1000 nm and to giant unilamellar vesicles over 1000 
nm (Jesorka and Orwar 2008). Phosphatidylcholine (PC), cholesterol and lipid-
conjugated polymers are the main components used in most liposome formulations 
(Mishra et al. 2011). The lipid composition, size, charge and surface modifications of 
the liposomes by attaching polymers, antibodies or other ligands can be easily done  
(Honda et al. 2013). Liposomes can interact with cells by four ways: 1) adsorption to 
the cell surface and the drug entrance via micropinocytosis, 2) fusion with the cell 
membrane and release of the cargo into the cytoplasm, 3) transfer-protein-mediated 
lipid exchange and 4) receptor-mediated endocytocis (Torchilin 2005). Photodynamic 
therapy involving liposomal verteporfin (Visudyne) is currently the only liposome 
formulation on market for posterior eye disease, and the first drug product approved by 
FDA for the treatment of wet AMD. After the intravenous administration of the 
liposomal verteporfin, the non-thermal laser light is used to irradiate the retina, which 
activates the photosensitizer (verteporfin) resulting in local damage to neovascular 
endothelium and closure of subfoveal blood vessels (Woodburn et al. 2002).  
 
Liposomes potential for posterior segment drug delivery lie in various promising 
qualities: they are biocompatible, they can be taken up by various cell types, their lipid 
membranes can be modified in order to increase targeting to specific cell types, and 
their content release can be controlled externally by physical of chemical triggers 
(Ebrahim et al. 2005). Liposome encapsulation increases the circulation half-life of a 
drug in the blood and shields the healthy tissues from toxicity. They can be passively 
targeted to tumors and other neovascular tissues via extravasation into leaky 
vascularized tissue. Besides the systemic administration, liposomes have been 
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experimentally administered also e.g. as intravitreal and subconjunctival injections and 
implantable depot devices to posterior segment. Prolonging the drug intravitreal half-
life and enabling targeted delivery to retinal tissues are the main interests of research of 
liposome-based posterior segment therapies. Systemic administration would enable 
avoiding the highly invasive intravitreal administration mode. 
 
Liposomes have been shown to hinder the clearance and prolong the vitreous half-life 
of several drugs. Liposome encapsulated ganciclovir was the first injectable intravitreal 
release system, and it has been studied both in animals and humans (Janoria et al. 2007). 
200–400 nm sized liposomes consisting of dipalmitoyl phosphatidylcholine, cholesterol 
and L-alpha-phosphatidyl-DL-glycerol with encapsulated ganciclovir were intravitreally 
injected in rabbit eyes (Le Bourlais et al. 1996). The liposome formulation had 22 times 
slower elimination time compared to the ganciclovir in simple solution, and provided 
greater than 50 % of inhibitory concentration (IC50) for CMV at least for 30 days and 
possibly up to 60 days. Fewer administrations of intravitreal injections of liposome-
encapsulated ganciclovir were needed compared to the free ganciclovir in the treatment 
of CMV retinitis of an AIDS patient (Akula et al. 1994). The monoclonal anti-VEGF 
antibody bevacizumab (Avastin) is approved for the treatment of colorectal cancer but 
off-labelly widely used to treat also several posterior ocular diseases. Intravitreally 
injected egg-PC or 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 
cholesterol containing liposome encapsulated bevacizumab average vitreal 
concentrations were approximately 2 times higher after 28 days and 5 times higher after 
42 days post-injection, compared to free bevacizumab in rabbit eyes (Abrishami et al. 
2009). PEG can be attached to liposomes to further improve the stability. PEG and 
positively charged cholesterol derivative conjugated liposomes injected to rats vitreous 
showed increased accumulation of doxorubicine to the retinal tissues compared to the 
neutral cholesterol derivative-PEG or plain PEG-conjugation (Geng et al. 2014). 
However, neutral PEG-coated liposomes would be more suitable choice to systemic 
administration, since the positive charged particles are cleared more effectively since 
they are more susceptible to bind with serum proteins and taken up by 
reticuloendothelial system.  
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Liposome encapsulation can stabilize and protect labile molecules, such as DNA or 
RNA based compounds and proteins, from the surrounding environment and preserve 
them from degradation. For example, antisense oligonucleotides have potential in 
treatment of intraocular viral infections but they suffer from poor stability (Bochot et al. 
2002). In rabbits, radiolabelled oligonucleotides encapsulated in PC/cholesterol/1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-amino-polyethylene glycol (DSPE-
PEG) liposomes were shown to retain in the vitreous and posterior tissues longer 
compared to the oligonucleotides in solution. Furthermore, the liposome formulation 
protected the oligonucleotides from degradation; the average percentage of intact 
oligonucleotides in the vitreous was 37.3 % in the liposomal formulation versus 0.5 % 
in simple solution. 
 
In several animal studies, liposome encapsulated drugs have shown decreased ocular 
toxicity compared to the free drug solution form, for example of amphotericin B and 
ofloxacin (Tremblay et al. 1985, Wiechens et al. 1999). That is due to the avoidance of 
peak concentration after an injection, and that reduced fraction of a free drug is 
available per time unit to directly contact the ocular tissues. 
 
The full knowledge about the fate of liposomes after intravitreal administration and 
their long-term effects remains still unknown (Eljarrat-Binstock et al. 2010). Lipid 
membrane of liposomes may be disrupted by interaction with proteins in the vitreous 
and possibly increase the risk of burst release and toxicity before reaching the target 
tissue (Bochot et al. 2000). Other related disadvantages of liposomes are difficulties in 
formulation, sterilization, encapsulation efficacy and stability in storage, and vitreal 
clouding after intravitreal injection (Yasukawa et al. 2004, Janoria et al. 2007, Honda et 
al. 2013).  
 
4.4 Other drug delivery systems 
 
Besides particle based carrier systems, other techniques such as iontophoresis or 
suprachoroidal microneedles have been studied to enhance transscleral drug delivery to 
posterior eye. 
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4.4.1 Transscleral iontophoresis 
 
Iontophoresis is based on the use of low-level electric current, which enhances the 
diffusion of charged molecules across biological membranes. Traditionally 
iontophoresis has been applied especially in transdermal drug delivery, but has gained 
interest in ophthalmology regarding to its non-invasive nature. In ophthalmology there 
are two main approaches, transcorneal or transscleral iontophoresis. Transscleral 
iontophoresis facilitates the drug delivery directly to the posterior segment. For 
example, therapeutic concentrations of cationic amicacin were reproducibly detected in 
the retina and choroid after transscleral iontophoresis in rabbits (Vollmer et al. 2002). 
OcuPhor, a hydrogel based iontophoretic system aiming to treat posterior chronic eye 
diseases was well tolerated by patients in phase I clinical trials (Parkinson et al. 2003). 
Eyegate II is another iontophoretic device that has been effective in patients (Halhal et 
al. 2004). Phase Ib/IIa clinical trial is enrolling patients for the delivery of 
dexamethasone in the treatment of macular edema (NCT02485249). The side effects 
associated to iontophoresis include mild discomfort and tissue damage which is 
dependent on the site of application, the density of current and the duration of the 
treatment (Parkinson et al. 2003, Eljarrat-Binstock and Domb 2006) 
 
4.4.2 Suprachoroidal microneedles 
 
Microneedles were also initially developed for transdermal drug delivery purposes. 
Suprachoroidally inserted microneedles have been shown to enable minimally invasive 
transscleral drug delivery of particle capsulated and free drug solutions in human 
cadaver eyes (Jiang et al. 2009). The method has potential in reaching the back of the 
eye since it bypasses the rapid conjunctival clearance by blood flow and it is minimally 
invasive and localized (Rai et al. 2015). Risks related to the suprachoroidal delivery are 
e.g. postoperative inflammation and choroidal hemorrhage, but the risk of 
complications is lower compared to the intravitreal injection. At the moment, one phase 
I/II clinical trial related to suprachoroidal administration of triamcinolone acetonide for 
non-infectious uveitis has been completed (NCT01789320), and phase II and III trials 
are ongoing and enrolling patients, respectively (NCT02255032, NCT02595398). 
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Table 2. Properties of different drug delivery system types. IVT = intravitreal injection. 
Modified from Eljarrat-Binstock et al. (2010), Edelhauser et al. (2010) and Del Amo 
and Urtti (2008).  
Method Advantages Disadvantages Duration of action 
Non-
biodegradable 
implants 
- Controlled release 
rate 
- Prolonged duration  
- Drug stabilization 
- Surgery or IVT required in 
order to insert or remove an 
implant à risk of 
complications increased 
- Risk of toxicity in case of 
implant breakdown 
Years 
Biodegradable 
implants 
- Prolonged and 
sustained release of 
drug 
- Drug stabilization  
- Removal of the 
implant usually not 
required  
- Surgery or IVT required in 
order to insert an implant à 
risk of complications 
- Possibly uncontrolled initial 
and final burst in drug release  
- Risk of toxicity in case of 
implant breakdown 
Weeks to months 
Cell 
encapsulation 
- Long lasting secretion 
of therapeutic protein 
- Avoidance of 
repetitive injections  
- Limited toxicity 
- Side effects related to the 
surgical operation in inserting 
or removing the implant 
- Risk of toxicity in case of 
implant breakdown 
Years, possibly longer 
periods 
Liposomes, 
polymeric 
micro- and 
nanoparticles 
- Increased drug half-
life by hindering the 
clearance 
- Enables local 
targeting  
- Declined peak 
concentration in drug-
release profile à 
decreased toxicity 
- Problems in stability in 
storage 
- Vitreous clouding 
- Possibly invasive injection 
required 
- Difficulties in sterilization 
and manufacture scale-up 
Days to weeks 
Transscleral 
iontophoresis 
- Minimally invasive 
- Decreased risk of 
toxicity 
- Can be used to a 
broad range of 
compounds 
- No sustained release, 
requires frequently repeated 
administrations 
à possibility of poor patient 
acceptance 
- Some patients experience 
mild pain  
Hours to days 
Suprachoroidal 
microneedles 
- Minimal invasiveness 
- Escapes conjunctival 
blood flow clearance 
à enhanced 
bioavailability 
- Risk of postoperative 
inflammation and choroidal 
hemorrhage  
Hours to months 
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5 FUTURE CHALLENGES AND PROSPECTIVES 
 
Gene therapy has potential in treating posterior segment diseases, and it has several 
advantages over conventional small molecular weight drugs (Borrás 2003). Genes can 
express their products for long periods of time, and the targeting of a certain gene in 
specific cell type can be achieved in a regulated way, which reduces the side effects in 
surrounding tissues. Nucleic acid based therapeutics, such as antisense oligonucleotides, 
DNA- or RNA-molecules (aptamers) or small interfering RNA have been investigated 
to target the abnormal protein expression in posterior segment diseases such as ocular 
neovascularization, CMV retinis or DR (Fattal and Bochot 2006). Nucleic acids have 
high molecular weight and a negative charge, being unable to cross the cornea. They are 
unstable in biological fluids making their intravitreal half-life short in simple solutions. 
Therefore, carrier-mediated delivery is needed to prolong their duration of action and 
enable the access to their intracellular targets. The carrier vehicles for gene delivery 
include viral, mainly adeno-accociated virus mediated or non-viral approaches. From 
non-viral systems especially micro- and nanoparticles and liposomes have considerable 
potential in delivering gene sequences to retinal and choroidal cells and enabling 
sustained delivery. 
 
The nanoparticle toxicity and possible immunological reactions, as well as their 
potential environmental risks must be acknowledged and carefully assessed (Diebold 
and Calonge 2010). The risks of nanosized particles include aggregation, accumulation 
to tissues, and adsorption of plasma proteins onto the particle surface. Safety of the 
most studied nanomaterials is usually well established in short period of administration, 
but yet there is not as much data about long-term administration of nanoparticles. It 
must also be acknowledged that a risk of severe ocular toxicity is associated to the 
polymer implants as well as ECT technologies in case of an implant breakdown. 
 
Kompella et al. (2013) stated few obstacles and future goals that the nanotechnology 
research has to answer in the future. Studies that systematically compare the different 
types of particles are to be conducted to obtain a better understanding of choosing the 
optimal particle for the certain drug, disease or delivery route. The nanoparticle 
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interactions with each other and with the microenvironment, e.g. membrane 
transporters, other tissue proteins, components in the vitreous and aqueous humor and 
blood, and which nanoparticle surface properties may alter these interactions must be 
evaluated. Hybrid systems combining different methods together, such as viral and non-
viral vectors or nanoparticles to microneedle administration are expected. 
 
The main challenge in design of posterior segment drug delivery lies in balancing 
between patient compliance and minimizing the costs and risks of complications, and 
on the other hand enabling efficient bioavailability, pharmacological response and 
optimal duration of the therapy. Multidisciplinary research and combining several 
techniques appears to be required in order to achieve these goals (Eljarrat-Binstock et 
al. 2010). The basic research to gain further understanding of the pathology of posterior 
eye disorders and the complex barriers restricting the access to the target tissues is still 
needed. In addition to discovery of new effective drug entities to treatment of posterior 
eye diseases, the research of drug delivery devices to enhance the delivery of already 
marketed molecules is essential. 
 
 
6 CONCLUSIONS 
 
Since blinding degenerative diseases attacking retinal and choroidal tissues are 
becoming more and more globally prevalent, the research focusing on providing 
efficient drug delivery to posterior segment has emerged.  Local and systemic treatment 
approaches at the moment suffer from poor bioavailability and systemic side effects. 
Posterior segment diseases are at the moment most efficiently treated with invasive 
means, including intravitreal injections that must be administered repeatedly due to the 
rapid clearance from the vitreous. Repetitive invasive injections carry a cumulative risk 
of complications and cause inconvenience to patients being burdensome to healthcare 
system. The main desirable attributes and goals are enabling sufficient bioavailability 
and efficacy, minimal invasiveness, safety, sustained and targeted delivery and 
decreased side effects. Patient compliance is a key factor to be considered. Promising 
results have been achieved with drug carrier delivery systems, such as sustained-release 
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implants and nano- or microparticles. Other techniques involving e.g. transscleral 
iontophoresis or microneedles have also gained interest among potential posterior 
segment treatment alternatives. 
 
 
EXPERIMENTAL WORK: IN VITRO EVALUATION OF LIGHT TRIGGERED 
AND PH-SENSITIVE LIPOSOMES WITH GOLD NANOPARTICLES  
 
 
7 INTRODUCTION  
 
There is a growing need to innovate intelligent drug carrier systems to the treatment of 
retina and other posterior tissues of the eye, to enhance the bioavailability, reduce off-
target side effects and prolong the duration of action and subsequently reduce the 
frequency of invasive procedures. This novel light triggered liposomal vehicle 
presented offers one approach to time- and place-controlled drug delivery. 
 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and DPPC containing liposomes 
with encapsulated gold nanoparticles are able to release their content in a controlled 
time point when exposed to UV-light (Paasonen et al. 2010). The liposomes are stable 
at 37 °C, but the light-induced heating of the gold nanoparticles by a plasmon resonance 
phenomenon induces the phase transition of the lipid bilayer from gel crystalline phase 
to leakier liquid crystalline phase, resulting to the temperature-dependent content 
release from the liposomes. Lajunen et al. (2015) developed a new thermosensitive 
formulation (DLD) that consists of DPPC, 1-stearoyl-2-hydroxy-sn-glycero-3-
phosphocholine (Lyso-PC), and DSPE-PEG. This formulation had a faster release rate 
compared to the previously introduced DSPC/DPPC liposome.  
 
The content release of liposomal drug carrier cannot be controlled on a cellular level 
with only light-sensitivity. To overcome this issue, the pH-sensitive domains 1,3-diolein 
and cholesterol-hemisuccinate  (CHEMS) were added to the liposome composition to 
make them stable at neutral pH but to release their content at acidic endosomal pH 
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(Lajunen et al. 2015). This improved pH- and light-sensitive formulation (D10pH) had 
promising content release profile; the calcein release from the liposomes was faster and 
more efficient in acidic conditions compared to neutral conditions. The liposomes were 
efficiently taken up by ARPE-19 and HUVEC cell lines, and did not show cytotoxicity 
in short-term viability studies. Light activation increased the intracellular release of 
calcein observed by confocal microscopy, while the release was not as efficient without 
light activation or without gold nanoparticles.  
 
The absorption wavelength of gold nanoparticles depends on the particle size and shape. 
Rod and star shaped nanoparticles were encapsulated to the liposome core. Their 
absorption wavelength is in visible and near-IR range, which improves the safety and 
tissue penetration properties since the light with longer wavelength is less toxic and 
more penetrative than UV-light. Fluorescent dye calcein is used as a marker of the drug 
release from the liposomes. Calcein has a self-quenching fluorescence in high 
concentrations when packed inside the liposome. As calcein is released from the 
liposome and the concentration diluted, the fluorescence is increased.  
 
Three different cell lines to model the target tissues of the posterior eye were utilized in 
the present study, using fluorescence-based methods fluorescence activated cell sorting 
(FACS) and confocal microscopy to measure cellular uptake and calcein release of the 
liposomes. ARPE-19, spontaneously arising human retinal pigment epithelium cell line 
is originally derived from the retina of 19-year old male donor in 1986 (Dunn et al. 
1996). In this experimental work ARPE-19 was used as a well-plate grown culture and 
as a Transwell filter-grown model. Culturing ARPE-19 on permeable membrane filters 
enhances the cell differentiation to exhibit the morphological and polarized 
characteristics of the retinal pigment epithelium in vivo (Dunn et al. 1996). 
 
New blood vessel forming of existing ones, i.e. angiogenesis or neovascularization, is 
involved in many pathological conditions including cancer, rheumatic inflammation, 
cardiovascular diseases, diabetes and vascular ocular diseases (Cao 2010, Carmeliet and 
Jain 2000). The endothelial cells cultured on reconstituted basement membrane 
matrixes, such as Matrigel, have been shown to differentiate rapidly to form capillary 
 33 
like tubules. The endothelial cell tube formation assay has become a widely used in 
vitro model of angiogenesis because of its quantitativity, easiness and usability to high-
throughput purposes (Arnaoutova et al. 2009). The model has been utilized e.g. in 
screening the efficacy of angiogenic or anti-angiogenic drug entities. Growth factors 
such as VEGF have an important role as pro-angiogenic regulators (Ferrara and Davis-
Smyth 1997). In this study, human umbilical vein endothelial cell line HUVEC was 
used both as a basic monolayer culture and as a tube formation model. HUVEC were 
treated with VEGF and cultured on Matrigel, to model the neovascularization typical 
for example the wet form of AMD (Favot et al. 2003, Ferrara and Davis-Smyth 1997). 
Another endothelial cell line from fetal Macala mulatta -rhesus monkey choroid, 
RF/6A, is also used in the present study as a model of choroidal endothelium. 
 
 
8 AIMS OF THE STUDY 
 
The aim of this master’s thesis is to continue studying the in vitro properties of light 
triggered and pH-sensitive liposomes using different endothelial and epithelial cell lines 
and growth conditions modeling the target tissues of the posterior segment of the eye.  
 
Study methods and objectives include: 
 
1) Cellular liposome uptake measured with flow cytometry 
2) Intracellular content release from liposomes observed with confocal microscope 
3) Cell viability using alamarBlue assay. 
 
The pH- and thermosensitive D10pH formulation was chosen as a primary formulation, 
but some studies were conducted also with the thermosensitive DLD formulation.  
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9 MATERIALS AND METHODS 
 
9.1 Gold nanoparticle liposomes 
 
Two formulations of encapsulated calcein containing gold nanoparticle liposomes 
previously described by Lajunen et al. 2015 were used in the experiments. These light 
activated thermosensitive liposomes and light activated pH- and thermosensitive 
liposomes were prepared by reverse-phase evaporation method. 
 
9.1.1 Preparation 
 
Lipids DSPC, DPPC, Lyso-PC and DSPE-PEG were purchased from Avanti Polar 
(Alabaster, AL, USA), and diolein and CHEMS from Sigma-Aldrich (St. Louis, MO, 
USA). The lipid stock solutions were obtained by dissolving in chloroform (Sigma-
Aldrich). The phospholipid mixture was prepared according to the Table 3. 
 
Table 3. Liposome formulations used in the experiments. Modified from Lajunen et al. 
2015. 
Formulation Abbreviation Lipid composition Molar ratios 
Light activated 
thermosensitive 
liposomes 
DLD DPPC / Lyso-PC / DSPE-
PEG 
90:10:4 
Light activated pH- 
and thermosensitive 
liposomes 
D10pH DPPC / DSPC / Lyso-PC / 
diolein / CHEMS 
10:90:15:15:10 
 
The chloroform was evaporated under nitrogen flow in a vacuum rotary evaporator 
system (Büchi R-114, Büchi Labortechnik AG, Flawil, Switzerland) at 60–65 °C, 
gradually lowering the pressure to 80 mbar, so that a thin lipid film was formed into the 
tube. The lipid layer was dissolved in 1.2 ml of di-isopropylether (DIPE, Sigma-
Aldrich). 
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The hydrophilic gold nanorods (rodNP, Sigma-Aldrich) with diameters 25 nm / 60 nm ± 
10 %, absorption maximum at 656 nm, concentration ≥45 µg/ml in H2O, stabilized with 
cetyltrimethyl ammonium bromide (CTAB) were concentrated beforehand by 
centrifuging and discarding the supernatant to achieve the final concentration of 0.3 mg 
/ 20 µl. Calcein solution of 60 mM and 280 mOsm was prepared by diluting 375 mg of 
calcein (Sigma-Aldrich) and 17 mg of sodium chloride (Sigma-Aldrich) in 10 ml of 
milli-Q water, and the pH was adjusted to 7.4 with sodium hydroxide solution. The 
lipid-DIPE solution, concentrated gold nanoparticles (20 µl) and 480 µl of calcein 
solution were heated to 60–65 °C in water bath, mixed and vortexed briefly in a glass 
tube. The tube was immediately moved into a bath ultrasonicator (Elmasonic S40H or 
Transsonic T310, Elma Schmidbauer GmbH, Singen, Germany) and the mixture was 
sonicated at 60–65 °C until a homogenized dispersion was obtained. Then, the tube was 
rapidly transferred into a pre-heated larger glass tube with 2 ml of milli-Q water, and 
the DIPE was evaporated in a vacuum rotary evaporator under nitrogen flow. The 
pressure was very carefully, during several hours, gradually lowered to 180 mbar 
avoiding foam or bubble formation. To ensure that the most of the organic solvent was 
evaporated, the solution was kept in the lowest pressure (180 mbar) for 10 minutes. 
Liposome solution with gold nanoparticles and calcein capsulated into the hydrophilic 
core was now formed. To decrease the size distribution of the liposomes the solution 
was again sonicated at 60–65 °C for 5 to 10 minutes depending on the batch (Figure 6). 
 
9.1.2 Purification and size analysis 
 
The liposome stock solution was purified by gel filtration using Sephadex G-50 column 
and buffer solution consisting of 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES, Sigma-Aldrich) and 140 mM sodium chloride (pH 7.4, 280 mOsm). The 
purified liposome sample was stored at 4 °C and used in experiments within 12 hours. 
The liposome gold concentration had previously been determined to be approximately 
50 µM in the purified sample (Lajunen et al. 2015). The size distribution of the prepared 
liposome stocks was analysed from purified sample by dynamic light scattering with 
Zetasizer APS (Malvern Instruments, Malvern, Worcestershire, UK).  
 
 36 
9.1.3 Temperature- and pH-dependent calcein release studies 
 
The calcein release as a function of temperature in HEPES or citric acid-phosphate 
buffer solutions at pH range 4.0–7.4 was determined. Citric acid buffer was prepared 
mixing appropriate volumes of 0.1 M citric acid monohydrate solution and 0.2 M 
disodium phosphate dehydrate solution. 250 µl of the buffer solution and 5 µl of the 
purified liposome solution was pipetted per well to a black/white 96-well plate (Perkin 
Elmer, Waltham, MA, USA). The calcein fluorescence was measured with Varioskan 
plate reader (Thermo Fisher Scientific Inc., Waltham, MA, USA), excitation and 
emission wavelengths being at 495 nm and 515 nm, respectively. Temperature was 
raised 2.5–5 °C at a time from 25 °C to 45 °C with 5 minute intervals, and the 
fluorescence was measured after each interval. After the run, 10 µl of Triton X-100 (MP 
Biomedicals, Santa Ana, CA, USA) was added to each well, and the fluorescence of 
entirely released calcein was now measured with Varioskan. The calcein release in each 
temperature point was calculated by formula: 
 𝑅(%) = 𝐹 − 𝐹!𝐹!"" − 𝐹!   ×  100%   
where F is the fluorescence intensity of the sample at a certain temperature, F0 is the 
baseline fluorescence intensity of the sample at 25 °C and F100 is the fluorescence 
intensity of the sample of completely released calcein after addition of Triton X-100. 
Since the fluorescence of calcein is pH-dependent, to calculate the release from D10pH 
liposomes each fluorescence value F was compared to the complete release value F100 in 
a certain pH. 
 
9.2 Light triggering 
 
All light activation studies were performed in a similar manner as described in Lajunen 
et al. (2015) on a heating plate (Thermo-Shaker PST-60HL, Biosan, Riga, Latvia) or in 
an incubator (Stuart SI60, Bibby Scientific Limited, Stone, Staffordshire, UK) at 37 °C. 
The light source consisted of WheeLED Wavelength-Switchable LED light source 
(Mightex Systems, Pleasanton, CA, USA), liquid light guide and a collimator with 
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focusing lens on it. The individual wells or dishes were irradiated with light for 20 min 
at a wavelength of 656 nm at power of 6 W/cm2.  The setup of light irradiation device is 
depicted in Figure 4. 
 
 
Figure 4. A light activation device setup. 
 
9.3 Cell cultures 
 
All cell lines were obtained from American Type Culture Collection (ATCC, Manassas, 
VA, USA). Following cell lines were used in experiments: ARPE-19 (ATCC® CRL-
2302™), HUVEC (ATCC® CRL-1730™) and RF/6A (ATCC® CRL-1780™). All cell 
culture media and reagents were bought from Gibco (Life Technologies, CA, USA) 
unless otherwise mentioned.  
 
9.3.1 ARPE-19 
 
ARPE-19 was grown in tissue-culture flasks in Dulbecco’s modified Eagle medium/ 
nutrient mixture F-12 (DMEM/F-12) supplemented with 1 % penicillin-streptomycin 
antibiotics, 1 % GlutaMAX and 10 % fetal bovine serum (FBS) in 37 °C / 7 % CO2 
incubator. The medium was changed every other day and the cells were passaged at a 
ratio of 1:2 to 1:7 once or twice per week. ARPE-19 cells were used in the experiments 
as passages 28–35 
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9.3.2 Filter-cultured ARPE-19  
 
To obtain a filter-grown ARPE-19 model, the cells were seeded on filters with 0.4 µm 
pore size polycarbonate (PCA) or transparent polyester (PET) membrane (Transwell, 
Corning, Corning, NY, USA). Firstly, the 24-mm, 12-mm and 6-mm diameter filters 
were coated with laminin (from mouse, 1 mg/ml, Corning). The laminin vial was 
thawed a night before coating in the fridge (4 °C) and kept on ice. The vial content was 
diluted in ice-cold DMEM/F12 medium to a final concentration of 67 µg/ml. An 
appropriate volume of the 67 µg/ml laminin solution was pipetted on each insert so that 
the coating density was 10 µg/cm2. The well plates were stirred and left to dry over an 
hour at room temperature with the lid closed. Then the plates were carefully rinsed with 
phosphate buffered saline (PBS) and dried in the laminar hood with the lid slightly open 
for 3–4 hours. 
 
After the incubation ARPE-19 cells of passages 24 and 27 were seeded on the plates. 
Cells from almost confluent flasks were detached and suspended into the ARPE-19 
insert medium, which is similar to the complete growth medium except the FBS 
concentration was lowered to 1 %. Appropriate volumes of ARPE-19 insert medium 
were added to the basolateral sides of the inserts just before seeding the cells. The 
seeding density was 160600 cells/cm2. The medium was changed the next day after the 
cell seeding, and twice a week thereafter. The plates were kept in 37 °C / 7 % CO2 
incubator, except during the first experiment (passage 24) the well plates were 
transferred from 7 % to 5 % CO2 incubator after 2 weeks of incubation due to the lab 
move regarding to the university renovation.  
 
The transepithelial electrical resistance (TEER) values were measured for the first time 
after two weeks of cell seeding with EVOM voltammeter (World Precision Instruments 
Inc., Sarasota, FL, USA) using STX2 electrode (World Precision Instruments Inc.). In 
the second experiment (passage 27) also Endohm chamber (World Precision 
Instruments Inc.) was used for measurements for 24- and 12-mm inserts. The TEER 
values were measured once a week, and the experiments with liposomes were carried 
out 4 weeks after cell seeding. The TEER values (Ωcm2) were determined by 
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subtracting the blank filter resistance (Ω) from the resistance of filters with cells, to 
obtain the resistance of the ARPE-19 cell layer. The resistances were then multiplied 
with the area of the filter (cm2). 
 
9.3.3 HUVEC 
 
Cells were cultured in F-12K/NutMix medium supplemented with 10 % FBS, 1 % 
penicillin-streptomycin, 1 % GlutaMAX, 0.1 mg/ml heparin (Sigma-Aldrich) and 0.05 
mg/ml endothelial cell growth supplement (Sigma-Aldrich). The medium was changed 
every other day and the cells were passaged 1–3 times a week with a subcultivation 
ratio of 1:2 to 1:3. Cell line was incubated in 37 °C / 5 % CO2 incubator. Passages 9–17 
of HUVEC cells were used in the study. 
 
9.3.4  HUVEC on Matrigel  
 
To induce the tube formation, the HUVEC cells were seeded on growth factor reduced 
(GFR) -Matrigel or GFR/phenol red free (PRF) -Matrigel (Corning) coated wells with 
protein concentrations of 8.3 mg/ml and 11.2 mg/ml, respectively. Matrigel starts to 
gelify in temperatures over 10 °C, and has to be handled with cold equipment. 
Therefore, the pipette tips and well plates were pre-cooled in −20 °C freezer several 
hours before the coating. Matrigel aliquot (0.1–2 ml) was thawed at 4 °C and kept on 
ice. Appropriate volume (40–280 µl depending on the area of the well) was pipetted on 
a well carefully avoiding bubble formation. The coatings were allowed to set for an 
hour in a laminar hood or overnight at 37 °C incubator. The HUVEC cells were 
suspended in complete growth medium supplemented with 25 ng/ml VEGF (Sigma-
Aldrich).  The appropriate amount of cells was seeded per well. The well plates were 
incubated 4–24 hours before the experiments were performed. 
 
An assay to determine the optimal cell seeding density for tube formation was 
performed. 50 µl and 280 µl of GFR-Matrigel were added per well on 96- and 24-well 
plates, respectively. The amounts of passage 11 HUVEC cells seeded per well on 24-
well plate were 40 000 (21 000 cells/cm2), 70 000 (37 000 cells/cm2), 100 000 (53 000 
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cells/cm2) and 120 000 (63 000 cells/cm2). The amounts seeded per well on 96-well 
plate were 10 000 (31 000 cells/cm2), 15 000 (47 000 cells/cm2), 20 000 (63 000 
cells/cm2), and 30 000 (94 000 cells/cm2).  
 
9.3.5 RF/6A 
 
Monkey choroid endothelial cell line RF/6A was grown in a minimum essential 
medium supplemented with 10 % FBS, 1.0 mM sodium pyruvate, 1 % GlutaMax and 1 
% penicillin-streptomycin. The cell line was incubated in 37 °C / 5 % CO2 incubator 
and passaged once or twice a week with a subcultivation ratio of 1:2 to 1:4. Medium 
was changed two to three times per week. Passages 37–42 of RF/6A cells were used in 
experiments.  
 
9.4 Flow cytometry 
 
The samples for the flow cytometry studies were prepared to observe the uptake of 
liposomes by cells. Appropriate density of cells was seeded on 96-, 24- or 12-well 
plates depending on the cell line. The seeding densities were 10 000 cells per 96-well 
(31 000 cells/cm2) or 165 000 cells per 12-well (43 000 cells/cm2) of ARPE-19 cells, 
5000 cells per 96-well of HUVEC cells, and 5000 cells per 96-well or 30 000 cells per 
24-well of RF/6A cells (15 000 cells/cm2). The optimized seeding density of HUVEC 
cells on Matrigel used was 21 000 cells/cm2. The cells were incubated for 48 hours at 
37 °C. The culture medium was aspirated and replaced with 150 µl, 900 µl or 1000 µl of 
serum-free medium to a 96-, 24- or 12-well, respectively. Next, 50 µl, 300 µl or 500 µl 
of purified liposome solution was added to the wells and the well plates were incubated 
for 20 minutes at 37 °C covered with foil to protect from light. After the incubation, in 
those experiments that included light activation the wells were emptied and refilled with 
150 µl, 900 µl or 1000 µl of serum-free medium, and each well was irradiated with light 
for 20 minutes. Subsequently, the medium was discarded and the wells were washed 
with PBS. 100 µl, 600 µl or 500 µl of trypsin-EDTA was added to the wells and 
incubated for 5 to 10 minutes at 37 °C until the cells were detached. The cells were 
fixed by adding 100 µl, 600 µl or 500 µl of 2 % paraformaldehyde (PFA, Sigma-
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Aldrich) and incubated at room temperature for 10 minutes. To obtain enough cells for 
flow cytometry measurements, several wells (3–10 wells per sample) were combined 
into an eppendorf tube, and centrifuged at 4 °C at 1000 g for 10 minutes. The 
supernatants were removed, and 200 µl of 2 % PFA was added and the eppendorfs were 
vortexed. The centrifugation and re-suspension was repeated. The eppendorfs were 
stored at 4 °C for maximum 7 days until the fluorescence activated cell sorting (FACS) 
measurements. Just before performing the flow cytometry measurements the samples 
were diluted in 500 µl of PBS.  
 
The liposome cell uptake studies for filter-cultured ARPE-19 cells were performed as 
follows. For 24-mm inserts, the control and liposome treated samples were prepared. 
For 12-mm inserts, also the light activated samples were made. Serum-free medium was 
changed to the basolateral sides of the inserts. The apical medium was replaced with 
500 µl of serum-free medium and 175 µl of purified liposome solution to the 12-mm 
inserts, or 2 ml of serum-free medium and 700 µl of purified liposome solution to the 
24-mm inserts, and the well plates were incubated for 20 minutes at 37 °C. For light 
activated 12-mm inserts the apical medium was then aspirated and replaced with 500 µl 
of serum-free medium, and each insert was irradiated with light for 20 minutes. Then, 
the inserts were washed thoroughly from the apical and basolateral sides with PBS. The 
cell detaching and fixation was performed the same way as with the other cell lines, 
using 350 µl or 1000 µl of trypsin-EDTA and 350 µl or 1000 µl of 2 % PFA for 12-mm 
inserts or 24-mm inserts, respectively. Two filters of ARPE-19 cells per sample were 
combined into eppendorf tubes, and centrifugations and re-suspensions were performed 
the same way as described above. 
 
The FACS measurements were performed with BD LSR II flow cytometer equipped 
with FACSDiva 8.0 software (BD Biosciences, San Jose, CA, USA) at the Flow 
Cytometry Core Facility in the Department of Biosciences, University of Helsinki. The 
results were analysed with Flowlogic software (Inivai Technologies, Mentone, Victoria, 
Australia). The baseline fluorescence threshold was determined from the untreated 
control sample. The threshold was set on the upper end (approximately at 98 % of the 
control peak intensity) of the fluorescence intensity histogram peak, and those cells 
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which fluorescence intensity exceeded that value were inferred to have taken up 
liposomes.  
 
9.5 Confocal microscopy 
 
To find out the light-induced intracellular release of calcein from the liposomes, 94 000 
ARPE-19 cells (9800 cells/cm2) or 62 700 HUVEC or RF/6A-cells (6500 cells/cm2) 
were seeded per confocal dish. 35 mm diameter dishes with 14 mm cover-glass bottom 
(MatTek, Ashland, MA, USA) coated with collagen for HUVEC and RF/6A, or with 
poly-D-lysine for ARPE-19 were used. Details of the experiments concerning ARPE-19 
on Transwell filters and HUVEC on Matrigel are discussed on separate chapters. The 
dishes were incubated for 48 hours at 37 °C, 5 % or 7 % CO2 depending on the cell line.  
 
First, the dishes were washed with PBS. 100 µl of purified liposome solution was added 
to the center of the dish and the appropriate medium was added dropwise so that the 
liquid stayed in the glass area. The dishes were incubated for 20 minutes at 37 °C 
protected from light. 2 ml of 4 % Hoechst 33258 solution (Sigma-Aldrich) in serum-
free medium was added to the dishes, and incubated for 10 minutes at 37 °C. The other 
dish was irradiated with light for 20 minutes in an incubator or at a warm plate, and the 
control dish was kept in the same conditions protected from the light. After the light 
activation the dishes were washed several times with PBS. 1–2 ml of serum-free 
medium was added, and the dishes were imaged with confocal microscope.  
 
Imaging was performed at the Light Microscopy Unit, Institute of Biotechnology using 
Leica TCS SP5II HCS -microscope (Leica Microsystems GmbH, Wetzlar, Germany) 
with HCX PL APO 63x/1.2 W Corr/0,17 CS water objective, or Leica TCS SP5 -
microscope with HCX APO L 63x/0.90 W dipping water objective (lasers: Ar 488 nm 
and UV 364 nm). Images were processed with Imaris 8.0 software (Bitplane AG, 
Zurich, Switzerland). 
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9.5.1 Confocal imaging of ARPE-19 on Transwell filters 
 
12-mm inserts were put on a transparent 35 x 10 mm Nunc cell culture petri dish 
(Thermo Scientific) and the handling procedure with liposomes and light was 
performed the same way as in other experiments. Since the microscope objective would 
not fit into the insert, the filter membrane was carefully cut with a scalpel and attached 
on to a petri dish with super glue (Loctite, Henkel-Norden, Stockholm, Sweden). 24-
mm inserts were also treated with liposomes and irradiated with light as described 
above. After the treatment and washings, the insert was glued as whole on the dish and 
imaged as such with Leica TCS SP5 -microscope with the dipping objective (Figure 5). 
 
 
Figure 5. Confocal imaging setup for 24-mm filter-grown ARPE-19. 
 
9.5.2 Confocal imaging of HUVEC on Matrigel 
 
There were two experiments done on subsequent days, which are marked as 
experiments 1 and 2. Firstly, the 14-mm glass areas of collagen-coated MatTek dishes 
were coated with 100 µl 1 or 80 µl 2 of GFR/PRF-Matrigel. 202 000 1 or 140 000 2 
HUVEC cells with 25 ng/l VEGF supplemented medium were seeded on the dishes. 
The dishes were incubated for 6 hours. The tube formation was monitored hourly by 
taking pictures with Leica DM IL LED inverted phase contrast microscope (Leica 
Microsystems) (Figure 1, Appendix 1). After the tube network had formed, the 
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liposome treatments and light activation were performed as described above. The 
confocal images were taken with Leica TCS SP5 -microscope with the dipping 
objective. 
 
9.6 AlamarBlue viability assay 
 
An alamarBlue cell viability assay (Invitrogen, Life Technologies, CA, USA) was 
performed to study the possible cytotoxic effects of the liposomes, gold nanoparticles 
and light irradiation. Specific details of the viability studies for filter-cultured ARPE-19 
and HUVEC tubes on Matrigel are discussed in separate chapters.  
 
10 000 ARPE-19 cells (31 000 cells/cm2) or 5000 HUVEC or 5000 RF/6A cells (16 000 
cells/cm2) were seeded per well on black/clear bottom 96-well plates (Corning) and 
incubated for 48 hours at 37 °C, 5 % or 7 % CO2 depending on the cell line. After the 
incubation, the culture medium was aspirated and replaced with 150 µl of serum-free 
medium and 50 µl of 50 µM purified liposome solution, 50 µM gold rodNP or star 
shaped gold nanoparticle solution (starNPs, produced by method described by Barbosa 
et al. 2010, with diameter 50–60 nm, coated with PEG used previously by Lajunen et al 
2015). 200 µl of serum-free medium was replaced to control wells. The well plates 
included three wells per sample. The cells for light exposure studies with controls were 
on a separate plate. The well plates were incubated for 24 hours.  
 
On the next day, 100 µl of serum-free medium was changed to the wells for light 
exposure studies. Individual wells were irradiated with light the same way as in other 
light activation studies described above. The wells contained cells treated with 
liposomes and untreated cells with only serum-free medium.  
 
After the incubations with liposomes and light activation, the wells were washed with 
PBS and 100 µl of 10 % alamarBlue reagent in serum-free medium was added per well. 
The plates were incubated for 3 hours at 37 °C, 5 % or 7 % CO2, after which the 
fluorescence was measured with Varioskan plate reader at a bandwidth of 5 nm with 
excitation and emission wavelengths of 570 nm and 585 nm, respectively. 
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9.6.1 Viability of filter-grown ARPE-19 cells 
 
AlamarBlue assay was performed on 12-mm and 6-mm filter-grown ARPE-19 with two 
inserts per sample. The basolateral insert medium was changed to serum-free medium. 
The apical medium was replaced with 150 µl of serum-free medium and 50 µl of 
purified liposomes or gold nanoparticle solution for 6-mm inserts, or 500 µl of serum-
free medium and 170 µl of purified liposomes or gold nanoparticle solution for 12-mm 
inserts, respectively. The well plates were incubated for 24 h at 37 °C. The light 
activation was performed for 6-mm inserts similarly as in other cell viability studies by 
changing 100 µl of serum-free medium to the apical side and irradiating individual 
wells with light for 20 minutes.  
 
After the light activation, the inserts were washed thoroughly with PBS. Serum-free 
medium was changed to the basolateral side of the inserts, and 100 µl of 10 % 
alamarBlue reagent to the 6-mm inserts or 500 µl to the 12-mm inserts, respectively, 
was added to the apical side. The well plates were incubated for 3 hours at 37 °C / 7 % 
CO2. After the incubation samples of 50 µl were taken from the apical side of each 
insert and put on a separate black/clear bottom 96-well plate. The fluorescence was 
thereafter measured with Varioskan plate reader.  
 
9.6.2 Viability of HUVEC capillary tubes on Matrigel  
 
3 wells per sample on a black/clear bottom 96-well plate were coated with 40 µl of 
Matrigel. The well plates were kept on 37 °C / 5 % CO2 incubator overnight. 7000 
HUVEC cells in VEGF supplemented medium were seeded per well (passage 11) and 
incubated for 4 hours at 37 °C / 5 % CO2. After the tubes had formed, the medium was 
replaced with 150 µl of serum-free medium and 50 µl of purified liposomes or gold 
nanoparticle solution, and incubated for 4 hours at 37 °C. The rest of the protocol was 
performed the same way as in other viability studies described above. 
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10 RESULTS  
 
10.1 Liposome size and calcein release 
 
The average liposome diameter per batch is depicted in Figure 6, and the calcein release 
curves as a function of temperature of the correspondent batches are gathered in Figure 
7. Since the last sonication time in the preparation process of the liposomes was altered 
between batches, the pH-sensitive liposome batches are numbered from D10pH-1–4 
and thermosensitive batches from DLD-1–2. The batches without gold nanoparticles 
(goldNP) are marked separately. It was noticed that the time of the last sonication is 
associated with size distribution and calcein release from the liposomes. Extending the 
time of the last sonication phase seemed to produce smaller and more uniform 
liposomes (Figure 6), whereas the calcein release was highest in batch D10pH-4 that 
was not sonicated. The calcein release from sonicated D10pH liposomes was overall 
modest. Batch D10pH-2 reached highest to 35 % calcein release in pH 4.0 at 45 °C. In 
non-sonicated batch D10pH-4 the calcein release in pH 4.0 was 57 % at its highest, but 
because of the big and wide size distribution profile that batch was not used in cell 
experiments. The calcein release of DLD was significantly higher compared to D10pH 
liposomes, as sonicated DLD-1 and DLD-2 batches reached to around 115 % and 70 % 
release, respectively (Figure 7).  
 
There were two different buffer solutions used in the calcein release measurements, 
which has to be taken into account when comparing the release profiles. For D10pH-1, 
DLD-1 and DLD-2 HEPES-NaCl buffer was used. For D10pH-2, D10pH-3, D10pH-4 
and D10pH without goldNP the measurements were performed in citric acid buffer. 
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Figure 6. The average size (nm) and the standard deviation of the liposome batches 
(n=2). Batches D10pH-1 and D10pH-4 include two repeats. The sonication time refers 
to the last sonication phase in the liposome production. 
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Figure 7. Calcein release (%) of the different liposome batches as function of 
temperature (°C). The error bars represent the standard deviations (n=3). The D10pH-1 
includes two repeats. D10pH-1 and DLD-measurements were performed in HEPES-
NaCl buffer (H), D10pH-2, -3, -4 and D10pH without goldNP in citric acid buffer (C). 
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10.2  Transepithelial resistance of filter-grown ARPE-19 
 
Calculated average TEER values (Ωcm2) of filter-cultured ARPE-19 are demonstrated 
in Figure 8. With the first set (passage 24) of ARPE-19 there was only STX2 electrode 
available to use in the TEER measurements. During the second set (passage 27) the 
Endohm chamber was also used. These two devices gave very different TEER values, 
especially for biggest 24-mm inserts. With STX2 electrode the TEER values were 
overall higher with more fluctuation compared to the ones measured with Endohm 
chamber, which gave more stable, though lower values.  
 
Figure 8. Average TEER values (Ωcm2) of filter-cultured ARPE-19. PCA = 
polycarbonate membrane, PET = polyester membrane. Values on the left graph 
measured with Endohm chamber and values on the right graph measured with STX2 
electrode. Error bars represent the standard deviations calculated from parallel inserts. 
 
The highest TEER values were achieved with large 24-mm filters, 70–100 Ωcm2 
measured with STX2 and around 40 Ωcm2 measured with Endohm chamber (Figure 8). 
12-mm filter-cultured ARPE-19 exhibited TEER values of 20–30 Ωcm2 measured with 
Endohm chamber, and 30–60 Ωcm2 and 20–40 Ωcm2 measured with STX2 from PCA- 
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and PET-membrane filters, respectively. Lowest TEER values were measured from 
small 6-mm filters (20–30 Ωcm2). Similar range TEER values for ARPE-19 cells in 
modified culture medium have been reported previously. With Endohm chamber 
measured values of ARPE-19 grown on 24-mm filters in literature range mostly from 
35–100 Ωcm2 (Ablonczky et al. 2011, Mannermaa et al. 2010) and 12-mm filter values 
around 30–40 Ωcm2 (Holtkamp et al. 1998, Dunn et al. 1996) 
 
Interestingly, with both sets of Transwell filter cultures of ARPE-19 the measured 
TEER values tended to decrease over time. For 12-mm inserts with both measurement 
devices the ratios between weeks 2, 3 and 4 were nearly the same, but for 24-mm insert 
the values were highly different. According to the Evom Instruction Manual (World 
precicion instrumens 2008) especially for low-resistance measurements the Endohm 
chamber produces more accurate and less variable results compared to the STX2 
electrode. STX2 appeared to be quite reliable TEER measurement device for 12-mm 
inserts, but for 24-mm inserts STX2 gave so variable TEER values that the values 
obtained with Endohm chamber were considered to be more accurate. The purpose of 
the filter-grown ARPE-19 model was to correspond in vivo condition better in general 
than a basic monolayer well plate culture, but strict barrier properties were not essential. 
Since complete monolayer uniformity was not required, like for instance in permeability 
studies, there was no exclusion criteria for TEER values implemented in this 
experimental work.  
 
10.3 Optimal cell seeding density assay for HUVEC tube formation on Matrigel   
 
The image collage from HUVEC tube formation assay on 24-well plate (well area 1.9 
cm2) and on 96-well plate (well area 0.32 cm2) is depicted in Figures 9 and 10, 
respectively. The best tube network was achieved with the seeding density of 40 000 
cells per 24-well (21 000 cells/cm2) (Figure 9-A). The network of capillaries was well 
formed with this density and there were only a few areas of cell clusters with no tubes. 
The cell cluster occurrence increased in relation to cell density. The optimal seeding 
density was therefore adjusted to be approximately 21 000 cells/cm2.  
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Figure 9. Microscope images (5x magnification) of optimal HUVEC cell density assay 
on Matrigel, 24-well plate (well area 1.9 cm2). A) 40 000 cells/well (21 000 cells/cm2), 
B) 70 000 cells/well (37 000 cells/cm2), C) 100 000 cells/well (53 000 cells/cm2), D) 
120 000 cells/well (63 000 cells/cm2). 
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Figure 10. Microscope images (5x magnification) of optimal HUVEC cell density assay 
on Matrigel coating, 96-well plate (well area=0.32 cm2). A) 10 000 cells/well (31 000 
cells/cm2), B) 15 000 cells/well (47 000 cells/cm2), C) 20 000 cells/well (63 000 
cells/cm2), D) 30 000 cells/well (94 000 cells/cm2). 
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10.4 Cellular uptake of liposomes 
 
The flow cytometry results with internalized percentages of liposomes for each 
experiment conducted on ARPE-19, HUVEC and RF/6A cell lines on well plates, 
HUVEC tubes on Matrigel and filter-grown ARPE-19 are presented in Table 4a-e. The 
light irradiated samples are gathered separately to Table 5, in which the mean 
fluorescence ratios between liposome treated and light activated samples are presented 
and compared. 
 
Table 4a-e. Cell uptake of the liposomes (%). In histograms the x-axis represents the 
fluorescence intensity (FITC-A) and y-axis the number of cells. The control samples are 
presented in green, liposome treated (lipo) samples in yellow and light activated (LA) 
samples in red color. 
Sample Internalized 
liposomes (%) 
Histogram 
a. Well plate grown ARPE-19 
Exp. 1) ARPE-19 treated with D10pH-1 liposomes on 12-well plate (repeated twice) 
Control 0 
 
Lipo 100.0 
Exp. 2) ARPE-19 treated with D10pH-3 –liposomes on 96-well plate 
Control 0 
 
Lipo 94.4 
LA 96.7 
 54 
b. Filter-grown ARPE-19  
Exp. 3) ARPE-19 cultured on 24-mm filters treated with DLD-1 
Control 0 
 
Lipo 88.9 
Exp. 4) ARPE-19 cultured on 12-mm filters treated with DLD-1 
Control 0 
 
Lipo 87.1 
LA 61.1 
Exp. 5) ARPE-19 cultured on 12-mm filters treated with D10pH-3 
Control 0 
 
Lipo 54.3 
LA 47.8 
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c. well plate grown HUVEC  
Exp. 6) HUVEC on 96-well plate treated with D10pH-3 
Control 0 
 
Lipo 37.9 
LA 50.1 
Exp. 7) HUVEC on 96-well plate treated with D10pH-3 
Control 0 
 
Lipo 35.5 
LA 31.2 
d. HUVEC capillary tubes on Matrigel coating 
Exp. 8) HUVEC cultured on GFR-Matrigel coating on 24-well plate treated with 
D10pH-1 
Control 0 
 
Lipo 53.9 
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Exp. 9) HUVEC cultured on GFR/PRF-Matrigel coating on 96-well plate treated with 
D10pH-3 
Control 0 
 
Lipo 6.2 
LA 2.8 
Exp. 10) HUVEC on GFR/PRF-Matrigel coating. Control samples cultured on 24-well 
plate and Lipo- and LA-samples on 96-well plate, and treated with D10pH-3 
Control 0 
 
Lipo 18.6 
LA 14.2 
e. RF/6A 
Exp. 11) RF/6A on 24-well plate treated with D10pH-3 
Control 0 
 
Lipo 93.1 
LA 90.1 
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Exp. 12) RF/6A on 96-well plate treated with D10pH-3 
Control 0 
 
Lipo 76.6 
LA 84.5 
 
There were noteworthy differences observed in liposome uptake between different cell 
systems. ARPE-19 and RF/6A cell lines internalized liposomes well, 94–100 % 
liposome uptake percentages in ARPE-19 and 76–93 % in RF/6A were measured (Table 
4a and e). Light activation increased the calcein fluorescence in ARPE-19 cells in 
experiment 2) and also in RF/6A experiment 12) by 1.10 and 1.85 fold, respectively 
(Table 5). Increased fluorescence in light activated samples suggests that intracellular 
calcein release from the liposomes may have occurred due to the calcein dilution. 
However, in other light activation study for RF/6A experiment 11) the calcein 
fluorescence was a bit lower in light activated sample, 0.90 fold compared to the sample 
without light irradiation (Table 5). 
 
Filter-cultured ARPE-19 cells internalized liposomes also rather well, 48–89 % of cells 
had taken up liposomes (Table 4b). However, there were two shallow “peaks” observed 
in the liposome treated samples of filter-cultured ARPE-19, most clearly seen in 
experiments 3) and 5) (Table 4b), suggesting that there might be two populations of 
cells which took up liposomes at different extents, some cells internalizing liposomes 
more efficiently than others. Light activation did not increase calcein fluorescence in 
either of the experiments, but actually decreased it (Table 5). 
 
Liposome uptake by HUVEC cells ranged from 31 to 50 % (Table 4c). In experiment 6) 
light activation increased the fluorescence intensity remarkably, by 1.73 fold (Table 5), 
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but in experiment 7) there was not much difference between liposome treated samples 
with or without light activation. 
 
The liposome uptake in HUVEC tube cultures on Matrigel differed much from the other 
cell systems studied (Table 4d). Interestingly, HUVEC tubes did not seem to internalize 
liposomes much in experiments 9 and 10, since only in 3–19 % of cells the fluorescence 
was higher than in untreated control cells. However, in experiment 8) without light 
activation the uptake percentage was higher, 53.9 %. The fluorescence was slightly 
increased after light activation in experiment 10), but decreased in experiment 9) (Table 
5). 
 
Table 5. Calcein fluorescence intensity ratios of light activated samples. MFR = mean 
fluorescence intensity ratio (mean fluorescence intensity of light activated sample / 
mean fluorescence intensity of the liposome treated sample). 
Exp. 
no. 
Cell line Liposome 
batch 
MFR Light activation 
increased 
fluorescence 
intensity (+/-) 
2 ARPE-19 D10pH-3 1.10 + 
4 ARPE-19 on filter DLD-1 0.55 -  
5 ARPE-19 on filter D10pH-3 0.73 - 
6 HUVEC D10pH-3 1.72 +  
7 HUVEC D10pH-3 0.93 - 
9 HUVEC on Matrigel D10pH-3 0.59 -  
10 HUVEC on Matrigel D10pH-3 1.06 + 
11 RF/6A D10pH-3 0.90 - 
12 RF/6A D10pH-3 1.85 +  
 
10.5 Light triggered intracellular calcein release  
 
10.5.1 Calcein release in ARPE-19 
 
The first confocal microscopy experiment performed was with D10pH-1 liposomes on 
ARPE-19 cells (Figure 11). The images obtained were overexposed due to the incorrect 
laser gain settings during the imaging, but there is still a slight difference seen in calcein 
distribution. In the control sample, the green fluorescent calcein inside the liposomes 
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are seen as vesicle like dots. In the light activated sample calcein seems to be a bit more 
diffused throughout the cytoplasm.  
 
CONTROL LIGHT ACTIVATED 
  
Figure 11. Confocal images of ARPE-19 treated with D10pH-1 liposomes. Calcein is 
shown in green and cell nuclei in magenta. 
 
The comparative study in ARPE-19 cells between D10pH and DLD formulations with 
and without gold nanoparticles is represented in Figures 12 and 13. The calcein 
intensity was very low in most of the images obtained. The most visible difference 
between control and light activated samples was observed in D10pH-2 treated ARPE-19 
cells, compared to the DLD-2 liposomes which did not show as notable difference in 
calcein distribution. Light activation did not have significant effect on calcein 
distribution for either liposome formulation without goldNP. 
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Figure 12. Confocal images of ARPE-19 treated with D10pH-2 liposomes and D10pH 
liposomes without goldNP. Calcein is shown in green and cell nuclei in magenta. 
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Figure 13. Confocal images of ARPE-19 treated with DLD-2 liposomes and DLD 
liposomes without goldNP. Calcein is shown in green and cell nuclei in magenta. 
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10.5.2  Calcein release in HUVEC and RF/6A cells 
 
The Figure 14 represents endothelial cells RF/6A and HUVEC treated with D10pH-2 
and D10pH-3 liposomes, respectively. In both experiments a mild difference in calcein 
distribution is observed, but the overall intensities were again very low. From these 
images the D10pH calcein release in HUVEC cells seems to be slightly better, 
especially in light activated HUVEC samples the green coloured calcein has a more 
“cloudy” formation compared to the control samples.  
 
The confocal imaging of HUVEC cells was also done with thermosensitive DLD 
liposomes (Figure 15). From these images it is difficult to make observations if the light 
irradiation releases calcein from DLD liposomes, because the images were again 
overexposed. 
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Figure 14. Confocal images of RF/6A and HUVEC treated with D10pH-2 and D10pH-
3, respectively. Calcein is shown in green and cell nuclei in magenta. 
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Figure 15. Confocal images of HUVEC cells treated with DLD-1. On left calcein is 
shown in green and cell nuclei in magenta. The correspondent bright-field images from 
the samples are on the right column. 
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10.5.3  Calcein release in filter-cultured ARPE-19 
 
The confocal images of the D10pH and DLD treated filter-cultured ARPE-19 are 
depicted in Figure 16. From the images it was noticed that the ARPE-19 cells layers 
were not forming a perfect monolayer, but the cells grew in two or three layers in some 
places. From the vertically taken image of the filter depicted in Figure 17 this can be 
seen: the green coloured calcein containing liposomes reach and absorb only into the 
top layer of ARPE-19 cells, whereas in underlying cells there is only magenta coloured 
nuclei seen, but no calcein containing liposomes.  
 
The differences in calcein distribution were again mild. In D10pH liposome treated 
samples there was hardly no difference seen from the images between control and light 
activated samples (Figure 16). In DLD treated samples the difference was a bit more 
notable, which may be considered as a likelihood of an light induced calcein release. 
From these images it can not though be conclusively concluded whether light activation 
releases calcein from the liposomes inside the filter-cultured ARPE-19. 
 
 
Figure 17. Vertically turned confocal microscope image taken of DLD-1 treated ARPE-
19 cultured on 12-mm filter. Calcein is shown in green and cell nuclei in magenta. 
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Figure 16. Confocal images of D10pH and DLD liposome treated ARPE-19 on filters. 
Calcein is shown in green and cell nuclei in magenta. 
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10.5.4  Calcein release in HUVEC capillary tubes 
 
The confocal microscope images taken of D10pH-3 treated HUVEC tube cultures 
grown on GFR/PRF-Matrigel are presented in Figure 18. Also bright-field images are 
included to demonstrate the tube-like structure orientation.  
 
Interestingly, the green coloured calcein was not seen almost at all in capillary 
structures between the cells, in neither control nor light irradiated samples. However, 
calcein was observed in some spesific areas. It was suspected that liposome uptake 
occurred actually in the cell cluster areas, where the cell density was higher. Because 
the calcein intensity was very low in both control and light irradiated samples, the 
conclusions about light induced calcein release were not able to be made. 
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Figure 18. HUVEC on GFR/PRF-Matrigel treated with D10pH-3 liposomes. On left 
calcein is shown in green and cell nuclei in magenta. The correspondent bright-field 
images from the samples are on the right column. 
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10.6 Cell viability 
 
Based on alamarBlue assay is was noted that liposome formulations D10pH or DLD, or 
star shaped gold nanoparticles at concentration of 50 µM did not decrease the viability 
of ARPE-19, HUVEC or RF/6A cells (Figure 19 A-E). Light activation at wavelength 
of 656 nm for 20 min did not either have a remarkable effect on viability for any of 
these cell lines. However, the rod-shaped gold nanoparticle treated cells showed around 
0 % viability compared to the control samples in ARPE-19, RF/6A and well plate 
cultured HUVEC. HUVEC tubes cultured on Matrigel were incubated with rodNP only 
for 4 hours, but for these samples the viability was also decreased to 70 % compared to 
the control (Figure 19 D). All of these results are similar with previously observed by 
Lajunen et al. (2015).  
 
The combined effect of the liposome treatment and light activation was studied with 
well plate cultured HUVEC and RF/6A cells, to see if the possible release of the 
contents of the liposomes would have any effect on cell viability, since it is known that 
naked rod-shaped nanoparticles are cytotoxic (Figure 19 C and E). These samples were 
treated with D10pH liposomes and then irradiated 20 min with light. For HUVEC cells, 
this treatment decreased viability a bit, 79 % compared to the control sample. For 
RF/6A, viability of D10pH treated and light irradiated was slightly higher than control 
(105 %), but a bit decreased compared to the sample with only light irradiation (111 %). 
Especially for HUVEC the released nanoparticles may have had toxic effects towards 
the cells in this single experiment, but more viability studies would be needed to make 
this conclusion, since these results may also be caused by normal biologic variation.  
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Figure 19 A-E. Cell viability (%) studied with alamarBlue assay. Lighter gray bars 
represent D10pH- or DLD-liposome formulations, and darker gray bars gold 
nanoparticle solutions at concentration of 50 µM. White bars and white bars with grey 
stripes represent light activated (LA), and liposome treated and thereafter light activated 
samples (D10pH+LA), respectively. Error bars represent the standard deviations (n=3). 
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11  DISCUSSION 
 
11.1  Problems in calcein release from pH-sensitive liposome formulation in buffer 
 
In the beginning of this experimental work it was noticed that the pH-sensitive liposome 
formulation D10pH was not showing as good calcein release profile as previously 
reported by Lajunen et al. (2015). In the first batch (D10pH-1) the highest calcein 
release achieved in pH 4.5 at 45 °C was around 22 %, whereas in Lajunen et al. the 
D10pH liposome formulation released almost 80 % of calcein at the same temperature 
in pH 4.5. In addition, concerning D10pH liposomes Lajunen et al. observed a 
remarkably more steep calcein release after temperature reached around 40 °C, but in 
the present study there was no similar “burst release” -effect seen. The release curves 
were steadily risen relative to temperature, being almost straight in all D10pH batches. 
However, there was a burst release effect clearly seen in all batches of DLD after 
temperature of 40 °C (Figure 7). Since the non-sonicated batch of D10pH had the 
highest release percentage of calcein (Figure 7), it can be assumed that the low calcein 
release profiles of D10pH liposomes may be partly due the calcein loss from the 
liposomes during the sonication. The liposomes are produced by reversed-phase-
evaporation method. This is a rather long process to carry out and includes multiple 
phases, making the production more difficult to be performed similarly between 
different batches. Liposome formulation, production reproducibility and calcein 
encapsulation efficiency are things to be assessed and optimized in the future, to obtain 
better release percentages. 
 
The study buffer for pH- and temperature-dependent content release studies was 
changed from HEPES to citric acid buffer. We assumed that the HEPES buffer capacity 
might be insufficient to maintain the acidity of the liposome solutions, and wanted to try 
out if that was the reason for poor calcein release results. Yet, the buffer change seemed 
not to have an effect on the calcein release efficacy from the pH-sensitive liposomes. 
 
Since the calcein release from the D10pH liposomes was not as efficient as was 
expected in the beginning of this experimental work, some cell studies done next were 
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conducted with the DLD formulation. We decided to perform a comparative confocal 
microscopy study with D10pH and DLD liposomes on ARPE-19 cells in terms of 
cytosolic calcein release, to see which formulation released calcein better after light 
activation. Confocal microscope images were taken of ARPE-19 cells treated with 
D10pH or DLD liposomes with or without gold nanoparticles (Figures 12–13). From 
this study the D10pH formulation with gold nanoparticles showed a greatest difference 
in calcein distribution when comparing the control and light activated samples. 
Apparent calcein release was not observed from either of the liposome formulation 
without nanoparticles.  
 
According to more promising intracellular release observed, the rest of the cell 
experiments were performed with the pH-sensitive D10pH formulation. One reason 
why the calcein release from D10pH liposomes in buffer solution was modest but in 
some cell studies the release seemed to occur, is because the simple buffer solutions can 
not conclusively represent the microenvironment conditions in much more complex cell 
systems. The more complex system in question, the more factors there are present to 
affect the local conditions that the nanocarrier encounters. The liposome content release 
results in buffer solutions versus in cell systems and subsequently in vivo can therefore 
vary extensively. 
 
11.2  Cellular liposome internalization and light triggered calcein release 
 
Based on FACS studies the liposome uptake by cells was variable depending on the cell 
system. ARPE-19 and RF/6A cells internalized liposomes rather well, but the 
internalization of liposomes by HUVEC cells and especially HUVEC tube cultures on 
Matrigel was less efficient, as well as in filter-cultured ARPE-19 the uptake percentage 
varied greatly between experiments. In previous studies Lajunen et al. (2015) got 
D10pH liposome uptake percentages of 99.9–100.0 % with both ARPE-19 and HUVEC 
cell lines. The uptake percentages for DLD liposomes were 99.9 % and 96.1 % for 
ARPE-19 and HUVEC, respectively. In the present study the uptake percentages of 
ARPE-19 were at similar range, but the results with HUVEC were significantly smaller, 
in range of 31–50 % (Figure 4c).  
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One possible reason to the difference in liposome uptake of HUVEC cells compared to 
the previously obtained results is that during present flow cytometry studies it was 
noticed that it was difficult to obtain enough endothelial cells to conduct the flow 
cytometry measurements. The cells were preferred to be cultured on 96-well plates 
because bigger well plates were not optimal for light irradiation treatments. Therefore, 
several 96-wells were combined per sample to obtain enough cells for flow cytometry 
studies. The amount of wells was limited to 3–5 wells with 5000 cells seeded in each 
well in HUVEC flow cytometry studies, because by using even more wells it would 
have required substantially longer time to prepare the samples. On the other hand, by 
preparing greater amount of cells per sample the possibility to obtain more reliable 
results would have increased. 
 
Also HUVEC tube formation assay turned out rather difficult to optimize in this 
experiment, which may have had an effect to the results. The tube formation occurrence 
varied highly between the experiments, in some studies the tubes were not formed at all 
in some wells, or the cell density was so high that there were only clumped HUVEC 
cells with only a few tube structures. After the tube network had been formed the 
disintegration of the tubes was observed to occur after a couple of hours. During the 
first tube formation studies in this experimental the HUVEC tubes were let to incubate 
for as long as 24 hours before the liposome treatments. When it was noticed that the 
tubes start to decompose in a few hours after the formation, the incubation time after 
cell seeding and liposome treatments was shortened. This might be one explanation, 
why in flow cytometry experiment 8 (Table 4d) the liposome uptake percentage was 
much higher than in other two, later performed experiments 9 and 10: the tube–cell 
cluster ratio might have been smaller in the first experiment 8 due to the longer 
incubation time induced tube network disintegration. Also the suboptimal cell amounts 
for flow cytometry studies may possibly have affected the results. 
 
These flow cytometry and confocal microscopy results give ground to suppose that 
HUVEC capillaries formed on Matrigel do not take up liposomes, although the HUVEC 
cells cultured on a well plate without basement membrane matrix do. The impact of this 
observation has to be figured out when desinging a drug delivery vehicle targeting the 
 74 
capillary vasculature. However, caution must be paid when interpreting results of in 
vitro angiogenesis assays. Endothelial cells cultured on Matrigel may not resemble 
properly the differentiation and morphology of the capillaries formed in vivo (Donovan 
et al. 2001). There has been a debate going on whether Matrigel cultured endothelial 
cells contain proper lumens. It has also been reported that Matrigel may also enhance 
the differentiation of several non-endothelial cell types to form tubules. The protein 
concentration of Matrigel batch, cell density, cell passage and amount of basement 
matrix material applied can all affect the tubule formation, and have to be optimized in 
the setup of this type of an assay (Arnaoutova et al. 2009, Auerbach et al. 2003). To 
conclude, even if in the present study the liposome uptake was low with HUVEC 
capillary tubes on Matrigel, it does not necessarily mean that the endothelial capillaries 
in vivo could not take up liposomes. Several assays on different matrixes are 
recommended to confirm any results obtained from angiogenesis assays (Staton et al. 
2009). Additional studies in vitro and in vivo are required to define the liposome uptake 
by choroidal neovasculature. 
 
Light induced intracellular calcein release studies by confocal microscopy gave also 
very variable results. The overall calcein intensity was very low in many of the 
experiments. In some experiments based on confocal images obtained the calcein 
release after light activation was assumed to occur in some extent. Large variation in 
calcein release results between experiments can be mostly due to the study arrangement 
related factors, such as temperature control and complex liposome production process. 
Also, this method was based purely on visual examination of the confocal images, and 
the fluorescence intensity was not quantitatively measured. In FACS studies the light 
activation increased calcein fluorescence only in 4 of the 9 experiments conducted, but 
these results are more directional than precise. Based on these results from confocal 
microscopy and FACS, the impact and significance of light triggering in encapculated 
calcein release cannot be excluded but should be studied further with more optimized 
study settings. The problems in study arrangement which may have influenced the 
results are discussed in following chapters. 
  
 75 
ARPE-19 cultured on filter exhibited comparable TEER values to the literature. 
However, it was noticed that the cells grew in several layers instead of a monolayer, 
which might have hampered the liposomal uptake and intracellular calcein release. 
Based on the FACS and confocal microscopy results it was assumed that the liposomes 
were internalized by only the upper layer of cells in the filter culture. Since the confocal 
microscopy imaging of Transwell filters turned out to be tricky to carry out with this 
method described, it is recommended that optimization of assay with filter-grown 
ARPE-19 must be continued in order to achieve more reliable results. 
 
One other aspect that might cause the modest intracellular calcein release after light 
activation in all of the cell systems was difficulties in temperature control during the 
experiments. We supposed that the temperature rise achieved with gold nanoparticle 
plasmon resonance after light irradiation might not be high enough to sufficiently 
induce liposome bilayer phase formation and content release. We started to pay 
attention on monitoring the temperatures after we discovered by the several 
thermometers that the temperature in liquid inside the incubator was not at 37 °C where 
it was set. Also the images taken by infra-red thermometer (Flir Systems, Wilsonville, 
OR, USA) supported this observation (Figure 20). According to the thermographic 
camera, the temperature in the liquid area in confocal dish was only 32.1 ± 1°C in the 
incubator set to 37 °C after the 20 min light irradiation in cytosolic calcein release 
study.  
 
After this observation we started to perform the light activation procedure on a heating 
plate instead of an incubator to gain more control of the temperature. The temperature in 
the liquid was monitored with a thermometer from the bottom of the well plate or a 
dish, and the heating plate thermostat was set so that the measured temperature in the 
bottom of the well plate or dish was 37 °C. This method was also noticed to involve 
difficulties. The temperature in different parts of the heating plate was noticed to vary 
significantly. Also, during viability studies the sensitive endothelial HUVEC and RF/6A 
cells were noticed to die almost completely after incubation on the heating plate when 
the temperature was monitored with thermometer, which indicates that the temperature 
was after all set too high. Afterwards, when looking the flow cytometry results, the cell 
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death after light activation would partially explain the decreased fluorescence intensities 
in light irradiated cell populations, especially concerning the endothelial HUVEC and 
RF/6A (Table 5). Problems in temperature control would certainly have affected also 
the cytosolic calcein release. The issue of temperature control must definitely be 
improved in further studies. 
 
 
Figure 20. A confocal dish (blue coloured cylinder) in an incubator set to 37 °C. The 
temperature in the confocal dish in the liquid is only 32.1 (± 1°C) according to the 
thermographic camera. 
 
11.3  Liposome cytotoxicity 
 
Sufficient biocompatibility is essential when designing a nanoparticle system to the 
clinical use. According to the present study, the 24-hour incubation with either DLD or 
D10pH liposome formulations did not decrease the cell viability. However, the plain 
rodNP reduced the viability of the cells remarkably, as was expected. Rod-shaped gold 
nanoparticles have shown strong cytotoxicity in some of the previous reports, possibly 
due to the cationic detergent CTAB which is used as a stabilizer in rodNP preparation 
(Yu et al. 1997). The toxicity of rod-shaped nanoparticles is supposed to be caused by 
the free CTAB detached from the surface of the rodNP, but not actually the rodNP 
themselves (Alkilany et al. 2009). Modifying the rodNP with e.g. PEG or 
polystyrenesulfonate has been shown to decrease the cytotoxicity (Niidome et al. 2006, 
Wang et al. 2008). However, the star-shaped nanoparticles did not show any 
cytotoxicity in the present study. In addition to better biocompatibility, starNP would be 
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an attractive alternative to rodNP because of the higher and wider absorption peak, 
allowing the use of longer wavelength of release activating light.  
 
Liposome formulations without gold nanoparticles did not show evident differences in 
calcein release with or without light exposure in ARPE-19 (Figures 12 and 13). That 
suggests that gold nanoparticles have an essential role in liposome content release. 
However, the biocompatibility of gold nanoparticles in vivo raises questions. 
Assessment of the impact of possible chronic uptake of gold nanoparticles by 
reticuloendothelial system and accumulation to spleen and liver is crucial. 
Recommended criteria for metal nanoparticles to be renally cleared include their 
degradation to components having hydrodynamic diameter of 5–6 nm (Choi et al. 
2007), which is remarkably smaller than with these goldNP used (25 nm/60 nm for 
rodNPs and 50–60 nm for starNP). Research activity about gold nanoparticle toxicity 
and biodistribution has been tremendously increased during last several years, with both 
supporting and opposing results of their biosafety (Khlebtsov and Dykman 2011). In 
many studies, toxicity has not occurred during short-term administration of gold 
nanoparticles but the research about long-term administration is still lacking. Further 
studies to draw correlations between the nanoparticle properties and their biological 
effect are needed. There are several other options besides gold nanoparticles to induce 
photophysical content release from liposomes, e.g. molecular dyes indocyanine green 
and sulforhodamine (Leung and Romanowski 2012). In the future, the long-term 
toxicity studies remain to be conducted in order to carefully assess the biosafety of these 
liposomal nanocarriers. 
 
11.4  Future prospects and clinical considerations 
 
It has been shown that liposomes can be internalized by several epithelial and 
endothelial cell types. The size distribution of the liposomes in this study varied highly, 
average diameter being 180–500 nm (Figure 6). This size may be too big to be 
topically, periocularly or systemically delivered to retina (Lajunen et al. 2014). In the 
literature, the size of most intravitreally injected liposomes range from 100–400 nm 
(Bochot and Fattal 2012). Average vitreous meshwork size is around 550 nm, and it has 
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been studied that particles below that size would be able to diffuse through the vitreous 
after intravitreal injection if their surface charge is optimal (Xu et al. 2013). Intravitreal 
delivery would so remain an achievable option to administer these liposomes. The 
smaller size of the liposomes would potentially enhance the movement and lengthen the 
half-life in the vitreous (Mains and Wilson 2013). Addition of targeting ligands can be 
used to further improve the delivery to RPE or choroidal endothelium. With this 
complex preparation method involving sonication and several phases it is difficult to 
produce homogeneously small liposomes in a reproducible manner. 
 
Light triggered drug delivery approaches offer one interesting method of targeted and 
controlled drug delivery vehicle to the treatment of the diseases attacking retina and 
other posterior tissues of the eye. Photodynamic therapy involving liposomal 
verteporfin (Visudyne) is already clinically used to subfoveal choroidal 
neovascularization. Eye can be easily irradiated with light through the pupil, and there 
are a wide range of different kinds of lasers already available in the field of 
ophthalmology. There have been other studies about liposomal light activated or pH-
sensitive systems to drug delivery purposes, but this is the first one to combine these 
synergistically (Lajunen et al. 2015). Retinal diseases are often characterized by 
pathologic lesions in a specific place. This kind of pH-sensitive system would gain 
more spatial and temporal control by allowing the intracellular drug release only in light 
irradiated area, which would diminish the unwanted side effects in the surrounding 
tissues.  For instance anti-VEGF agents in neovascular retinal diseases are currently 
given as frequently as once a month via intravitreal injection. By capsulating the 
therapeutic molecules in liposomal formulation prolonged release and longer time 
frequency between invasive injections would be possible, which would definitely 
increase the patient acceptance and quality of life. Furthermore, by reducing costs and 
the occurrence of possible complications the burden of the healthcare system would be 
reduced. 
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12 CONCLUSIONS 
 
The calcein release from the pH-sensitive D10pH liposome formulation in this present 
study was observed to be inferior compared to the previously published results. The 
cells internalized pH- and thermosensitive liposomes in a variable manner observed by 
flow cytometry and confocal microscopy. All cell systems internalized liposomes at 
some extent; HUVEC capillary uptake being somewhat negligible. The confocal 
microscope imaged calcein release after light irradiation was also variable, in some cell 
lines the release was more distinct than in others. Further optimization of the study 
setting, liposome production process and formulation may be needed to evaluate the 
impact of light triggering. Liposome formulations were non-cytotoxic within 24 hours, 
but the long-term safety is still to be studied. This liposomal drug carrier system 
possesses potential attributes, but optimization of the study arrangement is crucial in 
order to obtain more reliable results in a reproducible manner. Additional studies are 
needed to assess the future potential of these intelligent liposome formulations in the 
drug delivery to retina and possibly other pathologic target areas that are difficult to 
reach by conventional methods. 
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APPENDIX I: HUVEC tube formation on Matrigel basement membrane with time 
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Figure 1. Microscope images (5x magnification) of hourly-observed HUVEC capillary 
tube formation after cell seeding on Matrigel coated confocal dish. 
